var title_f1_14_1248="Photoaging topical tretinoin";
var content_f1_14_1248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of topical tretinoin in the treatment of photoaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Improvement of signs of photodamage after long-term treatment with tretinoin 0.05% emollient cream.",
"    <br/>",
"    (A) Baseline.",
"    <br/>",
"    (B) After 24 months of treatment.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin. Am J Clin Dermatol 2005; 6:245. Copyright &copy; 2005 Adis Data Information BV.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1248=[""].join("\n");
var outline_f1_14_1248=null;
var title_f1_14_1249="Doppler study lower extremity arteriovenous fistula";
var content_f1_14_1249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler study lower extremity arteriovenous fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duplex Doppler ultrasound image of a relatively small arteriovenous fistula developing after cardiac catheterization. The fistula, seen in red, involves a connection between the common femoral artery (CFA) and a branch of the greater saphenous vein (GSV). The site of the bruit is also noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1249=[""].join("\n");
var outline_f1_14_1249=null;
var title_f1_14_1250="Behcet disease uveitis";
var content_f1_14_1250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64705%7ERHEUM%2F63242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64705%7ERHEUM%2F63242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uveitis in Beh&ccedil;et's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widespread intraretinal hemorrhage from a patient with Beh&ccedil;et's disease. The hemorrhage is secondary to retinal vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal ischemia in Behcet's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph shows advanced retinal ischemia and optic nerve pallor in a patient with Behcet's disease and several previous attacks of severe vasoocclusive disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1250=[""].join("\n");
var outline_f1_14_1250=null;
var title_f1_14_1251="Tracheal foreign body";
var content_f1_14_1251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Foreign body in the trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The frontal radiograph demonstrates an apparent intratracheal foreign body, which proved to be the projection of a necklace over the tracheal gas column.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1251=[""].join("\n");
var outline_f1_14_1251=null;
var title_f1_14_1252="Eflornithine: Patient drug information";
var content_f1_14_1252=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eflornithine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37652?source=see_link\">",
"     see \"Eflornithine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vaniqa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3011945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vaniqa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the growth of unwanted facial hair in women.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take more than 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eflornithine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will still need to take off hair other ways while using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair bumps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 5 minutes after you get rid of hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wash affected part for at least 8 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Makeup may be used after the skin has dried.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12411 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1252=[""].join("\n");
var outline_f1_14_1252=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014270\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014269\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014274\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014275\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014277\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014272\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014273\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014278\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014279\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37652?source=related_link\">",
"      Eflornithine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_14_1253="Fetal acid-base physiology";
var content_f1_14_1253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fetal acid-base physiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1253/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1253/contributors\">",
"     Edward R Yeomans, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1253/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1253/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1253/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1253/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1253/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/14/1253/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal fetal metabolism results in the production of acids which are buffered to maintain extracellular pH within a critical range. Very small changes in pH may significantly affect function of various fetal organ systems, such as the central nervous system and the cardiovascular system [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1\">",
"     1",
"    </a>",
"    ]. The major buffers utilized by the fetus for neutralizing hydrogen ion production are plasma bicarbonate and hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/2\">",
"     2",
"    </a>",
"    ]. Inorganic phosphates and erythrocyte bicarbonate are also potential buffers, although they play a lesser role in fetal acid-base homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal hypoxia can occur when maternal oxygenation is compromised, maternal perfusion of the placenta is reduced, or delivery of oxygenated blood from the placenta to the fetus is impeded. When adequate fetal oxygenation does not occur, complete oxidative metabolism of carbohydrates to carbon dioxide (CO2) and water is impaired and metabolism proceeds along an anaerobic pathway with production of organic acids, such as lactic acid, which are not readily excreted or metabolized. Accumulation of lactic acid can deplete the buffer system and result in metabolic acidosis.",
"   </p>",
"   <p>",
"    Fetal acid-base physiology will be reviewed here. Interpretation of umbilical cord pH and blood gas values assessed immediately after delivery is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link\">",
"     \"Umbilical cord blood acid-base analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FETAL ACID-BASE PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus produces both volatile (carbonic acid) and nonvolatile acids (noncarbonic or organic acids).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Carbonic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus produces carbonic acid (H2CO3) during oxidative metabolism (aerobic glycolysis). Since H2CO3 is formed primarily from CO2 via hydration in the presence of erythrocyte carbonic anhydrase, the formation of carbonic acid is equivalent to CO2 generation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1\">",
"     1",
"    </a>",
"    ]. The rate of CO2 production, in turn, is equivalent to fetal oxygen consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the most part, the fetus can handle the amount of carbonic acid produced daily from aerobic metabolism since carbonic acid dissociates to water and CO2, which readily diffuses across the placenta. Diffusion of CO2 across the placenta is facilitated by a lower PCO2 in the mother during pregnancy, secondary to hyperventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Organic acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncarbonic or organic acids result from fetal anaerobic metabolism, which occurs when placental transfer of oxygen is restricted. Unlike carbonic acid, the organic acids are cleared very slowly across the placenta and therefore accumulate in the fetus. Metabolic acidemia develops when the primary buffer, bicarbonate (HCO3), as well as other buffers decrease to a critical level. The most important organic acids are lactic acid and ketoacids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Buffers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus utilizes many different buffers to maintain pH in a very narrow range. The two major buffers are bicarbonate and hemoglobin. Other buffers that play a lesser role include inorganic phosphates, erythrocyte bicarbonate, and albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The placenta also plays a significant role in helping to maintain a bicarbonate pool and buffering the fetus against changes in maternal pH or blood gas status. As an example, a study using a perfused human placental model reported acidification of the maternal side of the circulation did not significantly alter fetal acid-base status and there was efflux of bicarbonate from the placenta into the maternal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The level of bicarbonate is important in defining base deficit and base excess. A base excess exists when the fetal serum bicarbonate concentration is above normal, whereas a base deficit exists when the fetal serum bicarbonate concentration is below normal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Factors affecting fetal acid-base physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal perfusion of the placenta and the integrity of the fetal cardiovascular system affect fetal acid-base balance. As an example, maternal disorders such as preeclampsia, chronic hypertension,",
"    <span class=\"nowrap\">",
"     hypotension/hypovolemia,",
"    </span>",
"    and cyanotic heart disease can result in reduced uteroplacental blood flow and fetal oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1\">",
"     1",
"    </a>",
"    ], while obstetric complications such as placental abruption and cord prolapse can interfere with blood flow from the placenta to the fetus. During labor, fetal hypoxia and acidosis can be the result of repetitive cord occlusion.",
"   </p>",
"   <p>",
"    Rarely, alterations in maternal acid-base balance, such as renal tubular acidosis or diabetic ketoacidosis, result in fetal acidosis. Since fetal pH is normally 0.1 unit lower than that of the mother, maternal pH should be determined if fetal acidosis is suspected to be a passive result of maternal acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FETAL VERSUS ADULT ACID-BASE PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fetal acid-base physiology is similar to that of the adult, there are several notable differences. In the adult, the kidneys and lungs play a significant role in maintaining acid-base balance: respiratory and metabolic acidosis are the result of distinct clinical conditions. As an example, pulmonary disorders such as asthma, interstitial lung disease, or hypoventilation can lead to respiratory acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1\">",
"     1",
"    </a>",
"    ]. Likewise, diabetes mellitus, renal tubular acidosis, or diarrhea can lead to metabolic acidemia.",
"   </p>",
"   <p>",
"    By comparison, the fetus depends primarily upon the placenta to act as lungs and, to a lesser degree, kidneys to help compensate for acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Uteroplacental hypoperfusion is the major cause of both respiratory and metabolic acidemia, with progression from the former to the latter over time if decreased uteroplacental blood flow is not corrected (",
"    <a class=\"graphic graphic_figure graphicRef70673 \" href=\"UTD.htm?1/18/1324\">",
"     figure 1",
"    </a>",
"    ). Although the fetus can manifest a blood gas profile of a respiratory or metabolic pattern, acidosis most likely represents a continuum (mixed acidosis), rather than a distinct clinical entity. As an example, if uteroplacental perfusion is corrected during the respiratory phase, respiratory acidosis resolves as CO2 is rapidly cleared across the placenta. However, if the pathologic process is protracted, then in addition to excretion of CO2 being impaired, organic acids are produced and cleared very slowly across the placenta so that metabolic acidosis develops [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. Thus, fetal physiology is characterized by inability to compensate for acidemia by compensatory respiratory or renal responses in the same way and to the same degree as in the adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TERMINOLOGY FOR FETAL ACID-BASE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous terms used in describing fetal acid-base physiology and blood gas values [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acidosis &mdash; an increase in hydrogen ions in fetal tissue",
"     </li>",
"     <li>",
"      Acidemia &mdash; an increase in hydrogen ions in fetal blood. Respiratory acidemia refers to a low pH in the presence of a significantly elevated PCO2 and a normal serum bicarbonate concentration. Metabolic acidemia refers to a low pH with a normal PCO2 and low bicarbonate concentration. A mixed acidemia exists when bicarbonate concentration is low and PCO2 is elevated [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypoxemia &mdash; a decrease in oxygen content in fetal blood",
"     </li>",
"     <li>",
"      Hypoxia &mdash; a decrease in oxygenation of fetal tissue.",
"     </li>",
"     <li>",
"      Asphyxia &mdash; hypoxia with metabolic acidosis. Newborns with hypoxia severe enough to result in hypoxic ischemic encephalopathy (HIE) will usually exhibit an umbilical artery pH of less than 7.00 (often less than 6.90) and a base deficit greater than or equal to 12",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link\">",
"       \"Etiology and pathogenesis of neonatal encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Historically, asphyxia was defined by a low one-minute and five-minute Apgar score. This was not a reliable criteria because only 30 to 40 percent of newborns who are depressed (ie, have low Apgars) at birth are acidotic at delivery, which suggests that the depression is related to factors other than prolonged hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Both the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics consider use of the Apgar score in defining asphyxia as a misuse of this scoring system [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physiologically, asphyxia refers to interference or cessation of the respiratory process leading first to retention of CO2 (hypercarbia) and eventually to a significant reduction in oxygenation (hypoxia) and ultimately to metabolic acidemia. Since this process is difficult, if not impossible, to measure in the fetus, the terms",
"    <span class=\"nowrap\">",
"     acidosis/acidemia",
"    </span>",
"    and hypoxia are utilized in lieu of asphyxia. The diagnosis of intrapartum fetal asphyxia requires a blood gas and acid-base assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metabolic alkalosis rarely affects the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DETERMINATION OF FETAL ACID-BASE STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, acid-base status in fetal blood is evaluated by measuring its pH. Mathematically, the pH is the negative logarithm of the hydrogen ion concentration. The equation for pH is: pH = pK + log",
"    <span class=\"nowrap\">",
"     [HCO3-/PCO2].",
"    </span>",
"    In simpler terms, pH is directly related to the base component and indirectly related to the acid component. Thus, another way to write this equation is as follows:",
"   </p>",
"   <p>",
"    pH = pK + log [base",
"    <span class=\"nowrap\">",
"     (HCO3-)/acid",
"    </span>",
"    (H2CO3)]",
"   </p>",
"   <p>",
"    A general review of acid-base balance in adults can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9173?source=see_link\">",
"     \"Chapter 10A: Acids and bases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, pH in the adult is primarily controlled by renal bicarbonate excretion and pulmonary PCO2 excretion, while the placenta assumes these functions for the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;The critical pH level that should be used to define normal acid-base status is somewhat controversial. However, there are data to suggest that the cut-off for significant pathologic acidemia is a pH less than 7.00, and may even be a pH of less than 6.90 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1253/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link&amp;anchor=H4#H4\">",
"     \"Umbilical cord blood acid-base analysis\", section on 'Normal values'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antepartum assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no reliable, noninvasive method of determining fetal acid-base profile prior to delivery. Percutaneous umbilical blood sampling (PUBS) can be used to obtain fetal blood to determine fetal acid-base and blood gas values during the antepartum period. Although this technique has been useful in establishing the acid-base profile of fetuses in utero at various gestational ages (",
"    <a class=\"graphic graphic_table graphicRef76880 \" href=\"UTD.htm?9/1/9245\">",
"     table 1",
"    </a>",
"    ), its clinical utility is limited because of a high risk of procedure related fetal loss, particularly among fetuses who are compromised, and the need for serial examinations. Therefore, this technique is generally not recommended for antenatal fetal pH assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intrapartum assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal scalp blood sampling is a direct method for evaluation of intrapartum fetal acid-base status. However, this technique is rarely performed because it is cumbersome, requires repeated sampling and continuously available laboratory expertise, and is subject to error if there is scalp edema. Furthermore, simple noninvasive procedures, such as fetal scalp or vibroacoustic stimulation, often can provide reassurance of fetal well-being with indirect evidence of the absence of fetal acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal pulse oximetry provides continuous data on fetal oxygen saturation by a device inserted next to the fetal cheek. Randomized trials have not shown this technique to be clinically useful for intrapartum fetal monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link&amp;anchor=H25#H25\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Fetal pulse oximetry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Assessment at birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical cord blood sampling at birth provides an objective method of assessing the",
"    <span class=\"nowrap\">",
"     fetal/newborn",
"    </span>",
"    acid-base profile and provides useful information about intrapartum fetal status and obstetrical management. Guidelines for fetal acid-base determination via umbilical cord blood sampling and interpretation of fetal cord blood gas results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link\">",
"     \"Umbilical cord blood acid-base analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fetus, like the adult, maintains pH within a very narrow range.",
"     </li>",
"     <li>",
"      The two major fetal buffers are bicarbonate and hemoglobin.",
"     </li>",
"     <li>",
"      Unlike the adult, respiratory, metabolic, and mixed acidemia most likely represent a continuum in the fetus, rather than distinct clinical entities.",
"     </li>",
"     <li>",
"      The etiology of fetal acidosis is primarily uteroplacental hypoperfusion resulting in decreased fetal oxygenation and anaerobic metabolism.",
"     </li>",
"     <li>",
"      The placenta functions as both kidneys and lungs for eliminating fetal acids.",
"     </li>",
"     <li>",
"      Fetal CO2 crosses the placenta very rapidly, while fixed acids cross very slowly.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Nageotte, MP, Gilstrap, LC III. Intrapartum fetal surveillance. In: Creasy &amp; Resnik's Maternal-Fetal Medicine Principles and Practice, 6th ed, Creasy, Resnik, Iams, Lockwood, Moore (Eds), Saunders, Philadelphia, PA 2009. p.397.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/2\">",
"      Blechner JN. Maternal-fetal acid-base physiology. Clin Obstet Gynecol 1993; 36:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/3\">",
"      James EJ, Raye JR, Gresham EL, et al. Fetal oxygen consumption, carbon dioxide production, and glucose uptake in a chronic sheep preparation. Pediatrics 1972; 50:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/4\">",
"      Aarnoudse JG, Illsley NP, Penfold P, et al. Permeability of the human placenta to bicarbonate: in-vitro perfusion studies. Br J Obstet Gynaecol 1984; 91:1096.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham, FG, Leveno, KJ, Bloom, SL, et al. The newborn infant. In: Williams Obstetrics, 23rd ed, McGraw-Hill, New York, NY, 2010. p.590.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/6\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 348, November 2006: Umbilical cord blood gas and acid-base analysis. Obstet Gynecol 2006; 108:1319.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists (ACOG) and American Academy of Pediatrics (AAP): Neonatal encephalopathy and cerebral palsy: Defining the pathogenesis and pathophysiology. American College of Obstetricians and Gynecologists, Washington, DC, January 2003 p. 74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/8\">",
"      Page FO, Martin JN, Palmer SM, et al. Correlation of neonatal acid-base status with Apgar scores and fetal heart rate tracings. Am J Obstet Gynecol 1986; 154:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/9\">",
"      Low JA. The role of blood gas and acid-base assessment in the diagnosis of intrapartum fetal asphyxia. Am J Obstet Gynecol 1988; 159:1235.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice: Use and abuse of the Apgar score. No. 174, July 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/11\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn: Use and abuse of the Apgar score. Pediatrics 1986; 78:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/12\">",
"      Gilstrap LC 3rd, Leveno KJ, Burris J, et al. Diagnosis of birth asphyxia on the basis of fetal pH, Apgar score, and newborn cerebral dysfunction. Am J Obstet Gynecol 1989; 161:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/13\">",
"      Goldaber KG, Gilstrap LC 3rd, Leveno KJ, et al. Pathologic fetal acidemia. Obstet Gynecol 1991; 78:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1253/abstract/14\">",
"      Andres RL, Saade G, Gilstrap LC, et al. Association between umbilical blood gas parameters and neonatal morbidity and death in neonates with pathologic fetal acidemia. Am J Obstet Gynecol 1999; 181:867.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4439 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1253=[""].join("\n");
var outline_f1_14_1253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FETAL ACID-BASE PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Carbonic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Organic acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Buffers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Factors affecting fetal acid-base physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FETAL VERSUS ADULT ACID-BASE PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TERMINOLOGY FOR FETAL ACID-BASE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DETERMINATION OF FETAL ACID-BASE STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antepartum assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intrapartum assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Assessment at birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4439|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/18/1324\" title=\"figure 1\">",
"      Progression of fetal acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4439|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/1/9245\" title=\"table 1\">",
"      Umbilical Vein and Artery pH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9173?source=related_link\">",
"      Chapter 10A: Acids and bases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=related_link\">",
"      Umbilical cord blood acid-base analysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_14_1254="Immunotherapy for castration resistant prostate cancer";
var content_f1_14_1254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunotherapy for castration resistant prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1254/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1254/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1254/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1254/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1254/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1254/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1254/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1254/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/14/1254/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with advanced prostate cancer manifested by either metastases or a rising PSA after definitive therapy, androgen deprivation therapy (ADT) usually can provide disease control for a clinically significant period of time. Ultimately however, disease progresses in almost all cases. Patients who progress while on ADT are termed castration resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=see_link\">",
"     \"Initial hormone therapy for metastatic prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of the dendritic cell vaccine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     sipuleucel-T",
"    </a>",
"    and experimental immunotherapies for the management of castration resistant prostate cancer will be reviewed here. An overview to the approach to systemic therapy, including the role of different treatment options for castrate resistant disease, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer cells express a number of tumor-associated antigens that can serve as targets for immunotherapy. Examples include prostatic acid phosphatase (PAP), prostate specific antigen (PSA), and prostate-specific membrane antigen (PSMA).",
"   </p>",
"   <p>",
"    The poor in vivo immune response to many tumors, including prostate cancer, has been attributed to evasion of immune system recognition by decreased immunogenicity of surface antigens or blunted effectiveness of the immune response mounted against them. Several approaches have been studied to circumvent defective presentation of antigen to effector cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enhance the responsiveness of the patient's own immune system.",
"   </p>",
"   <p>",
"    Autologous dendritic cells can be used to deliver prostate cancer antigens for effective in vivo T cell activation. Dendritic cells, which can be harvested by leukapheresis, are efficient antigen-presenting cells that initiate an antigen-specific immune response via uptake, processing, and presentation of antigens to T cells.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     Sipuleucel-T",
"    </a>",
"    , a dendritic cell vaccine which induces immunity against PAP, can prolong overall survival and is commercially available. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Sipuleucel-T'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SIPULEUCEL-T",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     Sipuleucel-T",
"    </a>",
"    is an autologous dendritic cell therapeutic vaccine designed to enhance the immune T cell response to prostatic acid phosphatase. In randomized trials, sipuleucel-T prolonged survival compared to placebo dendritic cells and had a favorable safety profile.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     Sipuleucel-T",
"    </a>",
"    is prepared from peripheral blood mononuclear cells obtained by leukapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These cells are exposed ex vivo to a novel recombinant protein immunogen (PA2024), which consists of prostatic acid phosphatase (PAP) fused to human granulocyte macrophage colony-stimulating factor (GM-CSF). These activated cells are then infused back into the patient approximately three days after the original harvesting. Dendritic cell infusions are repeated for a total of three treatments at two week intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    results,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     sipuleucel-T",
"    </a>",
"    was studied in three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In the first two trials, the primary endpoint was progression-free survival, and overall survival was a planned secondary endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A subsequent, larger phase III trial was designed with overall survival as the primary endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/4\">",
"     4",
"    </a>",
"    ]. In all three trials, patients were randomly assigned in a 2:1 ratio to sipuleucel-T or a placebo vaccine, which consisted of mononuclear cells that had not been exposed to PA2024. Sipuleucel-T or the placebo was infused on weeks 0, 2, and 4.",
"   </p>",
"   <p>",
"    The patient population in each trial consisted of men with castration-resistant metastatic prostate cancer. Inclusion criteria required radiologic evidence of metastasis, a serum testosterone &lt;50",
"    <span class=\"nowrap\">",
"     ng/dL,",
"    </span>",
"    an expected survival of at least three months, and an ECOG performance status 0 or 1 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;Patients with visceral metastases or requiring opioid analgesics were excluded. Patients being treated with a gonadotropin releasing hormone (GnRH) agonist at enrollment were continued on it during therapeutic vaccine treatment. Patients assigned to the placebo were allowed to cross over to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     sipuleucel-T",
"    </a>",
"    if progressive disease developed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the initial two trials, progression-free survival was the primary endpoint. A combined analysis of the 225 men enrolled in these trials observed a statistically nonsignificant trend toward increased time to progression with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"       sipuleucel-T",
"      </a>",
"      compared with the control (11.1 versus 9.7 months, p = 0.11) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/2\">",
"       2",
"      </a>",
"      ]. Although the increase in progression-free survival was not statistically significant, overall survival, a secondary endpoint, was significantly longer in the sipuleucel-T group compared with placebo (median 23.2 versus 18.9 months, hazard ratio [HR] 0.67, 95% CI 0.49-0.91).",
"     </li>",
"     <li>",
"      Overall survival was the primary endpoint in the phase III IMPACT trial that enrolled 512 men [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/4\">",
"       4",
"      </a>",
"      ]. At a median follow-up of 34 months, patients assigned to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"       sipuleucel-T",
"      </a>",
"      therapeutic vaccine had a significantly improved overall survival with (median 25.8 versus 21.7 months HR 0.78, 95% CI 0.61-0.98). Differences in survival could not be accounted for by variations in subsequent treatment. As in the phase II trials, progression-free survival was not significantly prolonged (14.6 versus 14.4 weeks) and there were no significant differences in changes of serum PSA.",
"     </li>",
"     <li>",
"      Immunologic assessment of patients in the IMPACT trial provided additional evidence of an effect from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"       sipuleucel-T",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/4\">",
"       4",
"      </a>",
"      ]. Antibody titers against the PA2024 antigen were significantly more frequent in those treated with sipuleucel-T (66 versus 3 percent), as were antibodies against PAP phosphatase (29 versus 1.4 percent). In a prespecified analysis, survival was significantly longer in those with antibody responses to these antigens. T-cell proliferation responses to PA2024 and PAP were more frequent in those treated with sipuleucel-T (73 versus 12 and 27 versus 8 percent, respectively); however, the development of a T-cell response could not be correlated with a significant survival advantage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     sipuleucel-T",
"    </a>",
"    was generally well tolerated in all three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Side effects were related to the infusion of the therapeutic vaccine, were mostly grade 1 or grade 2, and usually resolved within one to two days.",
"   </p>",
"   <p>",
"    A combined analysis of the three trials compared the safety profile in 601 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     sipuleucel-T",
"    </a>",
"    and 303 treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/3\">",
"     3",
"    </a>",
"    ]. Adverse events more common with sipuleucel-T included chills, fatigue, fever, nausea, and headache (53 versus 11, 41 versus 35, 31 versus 10, 21 versus 15, and 18 versus 7 percent, respectively, compared to placebo). Cerebrovascular events were reported in 3.5 percent of patients treated with sipuleucel-T patients and 2.4 percent of patients who received placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role in patient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     Sipuleucel-T",
"    </a>",
"    therapeutic vaccine is an appropriate treatment option in asymptomatic or minimally symptomatic men (performance status 0 or 1) with metastatic, castration resistant prostate cancer. There are no data in men with castrate resistant prostate cancer whose only evidence of disseminated disease is an elevated serum PSA (so called &ldquo;M0 CRPC&rdquo;) or in those with more advanced disease (visceral metastases, using steroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    narcotics).",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     sipuleucel-T",
"    </a>",
"    significantly prolonged overall survival, it rarely induced disease regression and did not have a perceptible effect on radiographic progression-free survival. Furthermore, it did not induce consistent changes in the serum PSA level. Whether this is due to a delayed effect of immunotherapy or whether some other mechanism is involved is unclear. The absence of objective parameters to judge whether or not an individual patient is benefiting from vaccine therapy poses a major difficulty in determining when to consider sipuleucel-T ineffective and initiate alternative treatment.",
"   </p>",
"   <p>",
"    A number of other agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/29/44503?source=see_link\">",
"     abiraterone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16103?source=see_link\">",
"     enzalutamide",
"    </a>",
"    , taxane chemotherapy, radium 223) have also demonstrated improvement in overall survival in patients with castrate resistant prostate cancer (",
"    <a class=\"graphic graphic_table graphicRef85716 \" href=\"UTD.htm?17/56/18317\">",
"     table 2",
"    </a>",
"    ). However, there are no clinical trials that compare",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"     sipuleucel-T",
"    </a>",
"    with these other options. Factors to consider in choosing systemic therapy for men with castrate resistant disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link&amp;anchor=H261299183#H261299183\">",
"     \"Overview of the treatment of disseminated prostate cancer\", section on 'Sequence of systemic therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTI-CTLA4 IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic T cells are responsible for surveying and responding to a wide variety of antigens, a response that must be carefully regulated to prevent autoimmune reactions against self antigens. During cellular activation, various costimulatory signals act in concert with T cell antigen-receptor binding to promote or restrict full T cell activation. These costimulatory signals may be inhibitory or activating.",
"   </p>",
"   <p>",
"    One of the most important inhibitory costimulatory signals which restricts the T cell response to self antigens is mediated through the cytotoxic T lymphocyte antigen-4 molecule (CTLA4, also known as CD152) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/6\">",
"     6",
"    </a>",
"    ]. Binding of CTLA4 on a cytotoxic T cell to ligands on an antigen-presenting cell leads to T cell progeny that are less sensitive to stimulation by antigen.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    , a humanized, anti-CTLA4 monoclonal antibody, binds to the CTLA4 receptor on T cells and augments the immune response by blocking the interaction of CTLA4 with the B7 receptor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    has important antitumor activity in patients with metastatic melanoma and can prolong overall survival in that setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two phase III trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    with placebo are currently recruiting patients with metastatic castration resistant prostate cancer. One trial is evaluating this approach in patients with at least one bone metastasis who have received prior, prior treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (NCT00861614). The other trial is studying ipilimumab in patients who are asymptomatic or minimally symptomatic and who have not received prior chemotherapy or immunotherapy (NCT01057810).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MONOCLONAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches to simulate a T cell response are under study. As an example, monoclonal antibodies are being developed that target the programmed death 1 (PD-1) protein and the PD-1 ligand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175770315#H175770315\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Programmed death 1 protein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunostimulatory monoclonal antibodies to the prostate specific membrane antigen (PSMA) extracellular domain are also being developed, such as huJ591. Radiolabeled and unlabeled versions of huJ591 are being explored as therapy for prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/7-11\">",
"     7-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another PSMA-targeted monoclonal antibody, MLN2704, is conjugated to the maytansinoid antimicrotubule agent DM1. MLN2704 was evaluated in a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial in 61 men with progressive castrate-resistant prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/12\">",
"     12",
"    </a>",
"    ]. While there was some evidence of antitumor activity, grade 2 and 3 peripheral neuropathy was observed in all but the lowest doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROSTVAC-VF VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immunotherapy approach uses a vaccinia and fowlpox virus that is genetically engineered to contain a copy of the human PSA gene (called PROSTVAC-VF). This virus is combined with a proprietary \"cocktail\" of immune adjuvants to bolster the local immune response. In several phase I and phase II studies, treatment was well tolerated and toxicity was minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Objective PSA responses were seen, as well as stable disease for up to 19 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized phase II trial, 125 men with castrate-resistant prostate cancer and minimally symptomatic metastatic disease were randomly assigned to a PROSTVAC-VF plus GM-CSF or to an empty vector with a GM-CSF placebo for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/16\">",
"     16",
"    </a>",
"    ]. There was no statistically significant increase in progression-free survival, the primary endpoint of the study. However, there was an 8.5 month increase in overall survival (hazard ratio 0.56, 95% CI 0.37-0.85), a secondary endpoint of the trial.",
"   </p>",
"   <p>",
"    A phase III trial (NCT01322490) has been initiated in which 1200 asymptomatic or minimally symptomatic men are being randomly assigned to PROSTVAC-VF plus GM-CSF, PROSTVAC-VF plus a GM-CSF placebo, or to an empty vector [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1254/abstract/17\">",
"     17",
"    </a>",
"    ]. The primary endpoint of the trial is overall survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4111174\">",
"    <span class=\"h1\">",
"     SURVEILLANCE DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance strategies during treatment for disseminated prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link&amp;anchor=H11088148#H11088148\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Metastatic prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostate cancer cells express a number of tumor-associated antigens that can serve as targets for immunotherapy. The limited immune response to prostate cancer in vivo has been attributed to evasion of immune system recognition by decreased immunogenicity of surface antigens or blunted effectiveness of the immune response mounted against them. Several approaches have been studied to circumvent defective presentation of antigen to effector cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      enhance the responsiveness of the patient's own immune system. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"       Sipuleucel-T",
"      </a>",
"      is a dendritic cell vaccine made from autologous peripheral blood mononuclear cells that are pulsed with a fusion protein made from GM-CSF and prostatic acid phosphatase (PAP). Sipuleucel-T is an option for men with castration resistant metastatic prostate cancer who are asymptomatic or minimally symptomatic disease. In randomized trials in this setting, sipuleucel-T significantly prolonged overall survival. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sipuleucel-T'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The role of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/18/12581?source=see_link\">",
"       sipuleucel-T",
"      </a>",
"      in men with castrate resistant prostate cancer compared with other approaches that have also been shown to prolong survival is discussed separately (",
"      <a class=\"graphic graphic_table graphicRef85716 \" href=\"UTD.htm?17/56/18317\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link&amp;anchor=H261299183#H261299183\">",
"       \"Overview of the treatment of disseminated prostate cancer\", section on 'Sequence of systemic therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/1\">",
"      Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/2\">",
"      Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration package insert. (Available online at file://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf (Accessed on July 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/4\">",
"      Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/5\">",
"      Hall SJ, Klotz L, Pantuck AJ, et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 2011; 186:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/6\">",
"      Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 2006; 24:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/7\">",
"      Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/8\">",
"      Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/9\">",
"      Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23:4591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/10\">",
"      Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005; 11:7454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/11\">",
"      Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007; 25:540.",
"     </a>",
"    </li>",
"    <li>",
"     Milowsky MI, Galsky M, George DJ, et al. Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (abstract). J Clin Oncol 2006; 24:217s. (Abstract available online at file://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed March 23, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/13\">",
"      Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/14\">",
"      Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/15\">",
"      Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1254/abstract/16\">",
"      Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ (Accessed on April 26, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6937 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1254=[""].join("\n");
var outline_f1_14_1254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SIPULEUCEL-T",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role in patient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTI-CTLA4 IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROSTVAC-VF VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4111174\">",
"      SURVEILLANCE DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6937\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6937|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/56/18317\" title=\"table 2\">",
"      Therapies for castrate resistant prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=related_link\">",
"      Initial hormone therapy for metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_14_1255="Idiopathic acute eosinophilic pneumonia";
var content_f1_14_1255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic acute eosinophilic pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1255/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1255/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1255/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1255/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1255/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1255/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/14/1255/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic acute eosinophilic pneumonia (AEP) was first described as a cause of acute respiratory failure in 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Subsequently, cases of AEP have been reported worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Although both AEP and chronic eosinophilic pneumonia (CEP) are characterized by eosinophilic infiltration of the pulmonary parenchyma, these disorders are clinically distinct [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=see_link\">",
"     \"Treatment of chronic eosinophilic pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and management of idiopathic acute eosinophilic pneumonia will be reviewed here. Other conditions associated with pulmonary eosinophilia, and the approach to adults with diffuse parenchymal lung disease, are presented separately (",
"    <a class=\"graphic graphic_table graphicRef65178 \" href=\"UTD.htm?8/59/9148\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of AEP remains unknown. Some investigators have suggested that AEP is an acute hypersensitivity reaction to an unidentified inhaled antigen in an otherwise healthy individual [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/1\">",
"     1",
"    </a>",
"    ]. The following observations are consistent with this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In several reports, patients have been involved in unusual outdoor activities just prior to the onset of their illness [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/1,8-10\">",
"       1,8-10",
"      </a>",
"      ]. As an example, AEP developed in at least one firefighter following the collapse of the World Trade Center towers in 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/10\">",
"       10",
"      </a>",
"      ]. Another case developed in a young male smoker after he inhaled smoke from fireworks for three consecutive nights [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A temporal relation has been described in a number of patients between the development of AEP and the recent onset of cigarette smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8,12-19\">",
"       8,12-19",
"      </a>",
"      ]. In one patient, a cigarette-smoking challenge test led to recurrence of eosinophilic pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/13\">",
"       13",
"      </a>",
"      ]. In contrast, the process resolved in another case report despite continued cigarette smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eighteen cases of AEP were described among over 180,000 military personnel deployed in or near Iraq from March 2003 to March 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/15\">",
"       15",
"      </a>",
"      ]. All patients smoked, and the onset of smoking was recent in 14. All but one patient had significant exposure to fine airborne sand or dust; no other common source exposure could be identified.",
"     </li>",
"     <li>",
"      The possible role of environmental factors in the home was addressed in a study in which provocation challenges were performed in the homes of stable patients with a recent history of AEP [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/21\">",
"       21",
"      </a>",
"      ]. The challenge resulted in the development of a similar illness with fever, cough, fatigue, and dyspnea. Inspiratory crackles became audible and hypoxemia developed in all cases. Similar challenges at the patients' workplaces were negative. After moving out of their homes, the patients engaged in their usual work and experienced no recurrent episodes.",
"     </li>",
"     <li>",
"      Isolated cases of AEP have been described in HIV-infected patients, and following inhalation of cocaine or heroin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. The pathogenesis of these possible associations is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;AEP is a rare disease, and the clinical studies that are available have been retrospective in nature [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8,18,25\">",
"     8,18,25",
"    </a>",
"    ]. AEP can occur at any age, even in previously healthy children, though most patients are between 20 and 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Men are affected approximately twice as frequently as women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/1,2,9,28-31\">",
"     1,2,9,28-31",
"    </a>",
"    ]. A minority has a history of allergic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients present with an acute febrile illness of less than three weeks duration; in most cases the duration of symptoms is less than seven days. Nonproductive cough and dyspnea are present in almost every patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19\">",
"     19",
"    </a>",
"    ]. Associated symptoms and signs include malaise, myalgias, night sweats, and pleuritic chest pain.",
"   </p>",
"   <p>",
"    Physical examination shows fever (often high) and tachypnea. Bibasilar inspiratory crackles and occasionally rhonchi on forced exhalation are heard upon auscultation of the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19,31,32\">",
"     19,31,32",
"    </a>",
"    ]. Clubbing or signs of cor pulmonale have not been reported.",
"   </p>",
"   <p>",
"    Hypoxemic respiratory insufficiency is frequently identified at presentation and often requires mechanical ventilation. In one series, 14 of 22 patients (63 percent) developed respiratory failure and required mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8\">",
"     8",
"    </a>",
"    ]. Hyperdynamic shock has been reported, but is unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory studies are nonspecific and generally not helpful. Patients generally present with an initial neutrophilic leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8,12,19\">",
"     8,12,19",
"    </a>",
"    ]. In most cases, the eosinophil fraction becomes markedly elevated during the subsequent course of AEP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8,30,32\">",
"     8,30,32",
"    </a>",
"    ]. The erythrocyte sedimentation rate is elevated. The IgE level has been high in a majority of the patients in whom it was measured [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/21,28-31\">",
"     21,28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating levels of thymus and activation-regulated chemokine",
"    <span class=\"nowrap\">",
"     (TARC)/CCL17,",
"    </span>",
"    a functional ligand for CCR4 on Th2 cells, may prove to be a useful biomarker for discriminating AEP from other causes of acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When pleural fluid is present, it may demonstrate a marked eosinophilia with a high pH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/31,35\">",
"     31,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the onset of AEP, the chest radiograph may show only subtle reticular or ground glass opacities, often with Kerley B lines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/35\">",
"     35",
"    </a>",
"    ]. Most often, bilateral diffuse mixed ground glass and reticular opacities are seen on plain chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/1,2,9,28-31,36\">",
"     1,2,9,28-31,36",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50572 graphicRef71567 \" href=\"UTD.htm?36/1/36886\">",
"     image 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=see_link\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated ground glass (approximately 25 percent of cases) or reticular (approximately 25 percent of cases) opacities may also be seen on presentation. The pattern is unlike that seen in CEP, in which the opacities are localized to the lung periphery.",
"   </p>",
"   <p>",
"    Small pleural effusions are common (noted in up to 70 percent of patients) and are frequently bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8\">",
"     8",
"    </a>",
"    ]. The pleural effusion resolves more slowly than the pulmonary parenchymal opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/9\">",
"     9",
"    </a>",
"    ]. Following the institution of treatment, radiographs generally demonstrate progressive resolution over one to two months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29527?source=see_link\">",
"     \"Pleural fluid eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     High resolution CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution CT (HRCT) scans are always abnormal in patients with AEP, and are characterized by bilateral, random, and patchy ground-glass or reticular opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19,37\">",
"     19,37",
"    </a>",
"    ]. Centrilobular nodules and air-space consolidation are seen in approximately 50 and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19\">",
"     19",
"    </a>",
"    ]. In mild cases, the lesions are sparse or localized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/30,38\">",
"     30,38",
"    </a>",
"    ]. At the height of the disease process, HRCT reveals peripheral ground-glass opacities along the bronchovascular bundles. Pleural effusions, usually bilateral, are present in almost 90 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A restrictive process with reduced diffusing capacity for carbon monoxide is commonly identified [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/9\">",
"     9",
"    </a>",
"    ]. Lung function returns to normal after recovery from the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of bronchoalveolar lavage fluid (BAL) fluid often shows a very high percentage (&gt;25 percent) and total number of eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8,9,25,30,31\">",
"     8,9,25,30,31",
"    </a>",
"    ]. The proportions of BAL lymphocytes and neutrophils are also frequently increased. The level of eosinophilia returns to normal when the illness resolves [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/9,30,31\">",
"     9,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High levels of interleukin (IL)-5 have been found in the BAL fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. IL-5, produced mainly by T-helper lymphocytes, may play a pathogenetic role in AEP: it is a potent chemotaxin for eosinophils; causes the release of eosinophil granules; and prolongs eosinophil survival by inhibiting apoptosis.",
"   </p>",
"   <p>",
"    In addition, IL-1ra, soluble type II IL-1 receptor, vascular endothelial growth factor (VEGF), and granulocyte macrophage colony-stimulating factor (GM-CSF) have also been found in BAL fluid of patients with AEP, but their roles in the pathogenesis of AEP remain unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/6,40,42\">",
"     6,40,42",
"    </a>",
"    ]. The levels of these cytokines fall after resolution of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few patients with AEP have undergone lung biopsy other than by transbronchial biopsy, which yields small samples that are inadequate for complete analysis. One study evaluated nine open and thoracoscopic lung biopsies taken from the consultation and teaching files of the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/43\">",
"     43",
"    </a>",
"    ]. Key histopathologic features included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe extent of disease, with abnormalities in over 75 percent of the surface area of the lung sampled.",
"     </li>",
"     <li>",
"      Acute and organizing diffuse alveolar damage (DAD) was common. Hyaline membranes and interstitial widening (due to a combination of edema, fibroblast proliferation, and inflammatory cells characteristic of the organizing phase of DAD) were each seen in 78 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=see_link\">",
"       \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Marked numbers of interstitial and lesser numbers of alveolar eosinophils were found in all samples (",
"      <a class=\"graphic graphic_picture graphicRef74556 \" href=\"UTD.htm?11/12/11466\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other features included: type II pneumocyte hyperplasia (55 percent of cases), interstitial lymphocytes (100 percent of cases), an organizing intraalveolar fibrinous exudate (100 percent of cases), and perivascular and intramural inflammation without necrosis (33 percent of cases) (",
"      <a class=\"graphic graphic_picture graphicRef58648 \" href=\"UTD.htm?2/50/2858\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Granulomas and alveolar hemorrhage were absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AEP is a diagnosis of exclusion that requires [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acute febrile illness of short duration (usually less than one week)",
"     </li>",
"     <li>",
"      Hypoxemic respiratory failure",
"     </li>",
"     <li>",
"      Diffuse pulmonary opacities on chest radiograph",
"     </li>",
"     <li>",
"      BAL eosinophilia &gt;25 percent",
"     </li>",
"     <li>",
"      Lung biopsy evidence of eosinophilic infiltrates (acute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      organizing diffuse alveolar damage (DAD) with prominent eosinophilia is the most characteristic finding)",
"     </li>",
"     <li>",
"      Absence of known causes of eosinophilic pneumonia, including drugs, infections, asthma, or atopic disease (",
"      <a class=\"graphic graphic_table graphicRef65178 \" href=\"UTD.htm?8/59/9148\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"       \"Causes of pulmonary eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some authors suggest that the diagnosis can be made with confidence without lung biopsy in immunocompetent patients with a compatible history and prominent BAL eosinophilia in the absence of infection or other known precipitant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8,44\">",
"     8,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although spontaneous improvement following smoking cessation has been reported, many patients with AEP have progressive respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/8,19,29-31\">",
"     8,19,29-31",
"    </a>",
"    ]. Patients with AEP are uniformly responsive to intravenous or oral glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19,32\">",
"     19,32",
"    </a>",
"    ]. The response is often dramatic, occurring within 12 to 48 hours. If a patient fails to respond to glucocorticoids, an alternative diagnosis should be entertained.",
"   </p>",
"   <p>",
"    No trials have identified the ideal dose or length of glucocorticoid treatment, and initial therapy often varies based upon the severity of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of respiratory failure, initial treatment is with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (40 to 60 mg daily).",
"     </li>",
"     <li>",
"      In the presence of respiratory failure,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (60 to 125 mg every 6 hours) is given until respiratory failure resolves (usually within 1 to 3 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in a dose of 40 to 60 mg per day is then continued for two to four weeks beyond the complete resolution of symptoms and conventional chest radiograph abnormalities, which usually takes two to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19,35\">",
"     19,35",
"    </a>",
"    ]. At that time, the dose can be reduced by 5 mg every seven days until complete cessation of therapy. A shorter course with tapering and discontinuing of prednisone over two weeks has been reported in a case series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/19\">",
"     19",
"    </a>",
"    ]. The times to resolution of symptoms and radiographic abnormalities were comparable among the 42 patients treated for four weeks and the 85 patients treated for two weeks.",
"   </p>",
"   <p>",
"    Relapse is uncommon and is usually associated with resumption of cigarette smoking after initial cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1255/abstract/14,18,19,45\">",
"     14,18,19,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data on treatments other than glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic acute eosinophilic pneumonia (AEP) is a cause of acute respiratory failure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It differs from other eosinophilic pneumonias by its acute onset (usually less than seven days of symptoms), presence of fever, and acute hypoxemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AEP has been associated most often with new onset or resumption of smoking. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete blood count usually shows a neutrophilic leukocytosis; peripheral eosinophilia may develop over the course of the disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Analysis of BAL fluid often shows a high number of eosinophils (&gt;25 percent). Lung biopsy reveals eosinophilic infiltration: acute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      organizing diffuse alveolar damage with prominent eosinophilia is the most characteristic finding. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bronchoalveolar lavage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AEP is a diagnosis of exclusion. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with AEP be treated with glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although spontaneous improvement has been reported, the response to glucocorticoids is often dramatic with prevention or reversal of respiratory failure. The exact dose of glucocorticoid is guided by the degree of respiratory impairment and response to treatment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment and outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/1\">",
"      Badesch DB, King TE Jr, Schwarz MI. Acute eosinophilic pneumonia: a hypersensitivity phenomenon? Am Rev Respir Dis 1989; 139:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/2\">",
"      Allen JN, Pacht ER, Gadek JE, Davis WB. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 1989; 321:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/3\">",
"      Arrese M, Castell&oacute;n JM, Contreras G. [Eosinophilic pneumonia causing severe respiratory insufficiency. Clinical case]. Rev Med Chil 1991; 119:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/4\">",
"      Nishio M, Ohata M, Suruda T, et al. Idiopathic acute eosinophilic pneumonia. Intern Med 1992; 31:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/5\">",
"      Slabbynck H, Coeck C, Galdermans D, et al. Dyspnea, fever, and eosinophilia. Chest 1993; 104:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/6\">",
"      Balbi B, Fabiano F. A young man with fever, dyspnoea and nonproductive cough. Eur Respir J 1996; 9:619.",
"     </a>",
"    </li>",
"    <li>",
"     Cordier JF. Eosinophilic Pneumonias. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.657.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/8\">",
"      Philit F, Etienne-Mastro&iuml;anni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002; 166:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/9\">",
"      Pope-Harman AL, Davis WB, Allen ED, et al. Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. Medicine (Baltimore) 1996; 75:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/10\">",
"      Rom WN, Weiden M, Garcia R, et al. Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. Am J Respir Crit Care Med 2002; 166:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/11\">",
"      Hirai K, Yamazaki Y, Okada K, et al. Acute eosinophilic pneumonia associated with smoke from fireworks. Intern Med 2000; 39:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/12\">",
"      Miki K, Miki M, Nakamura Y, et al. Early-phase neutrophilia in cigarette smoke-induced acute eosinophilic pneumonia. Intern Med 2003; 42:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/13\">",
"      Watanabe K, Fujimura M, Kasahara K, et al. Acute eosinophilic pneumonia following cigarette smoking: a case report including cigarette-smoking challenge test. Intern Med 2002; 41:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/14\">",
"      Shiota Y, Kawai T, Matsumoto H, et al. Acute eosinophilic pneumonia following cigarette smoking. Intern Med 2000; 39:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/15\">",
"      Shorr AF, Scoville SL, Cersovsky SB, et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA 2004; 292:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/16\">",
"      Al-Saieg N, Moammar O, Kartan R. Flavored cigar smoking induces acute eosinophilic pneumonia. Chest 2007; 131:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/17\">",
"      Grossi E, Poletti G, Poletti V. Acute eosinophilic pneumonia with respiratory failure: a case likely triggered by cigarette smoking. Monaldi Arch Chest Dis 2004; 61:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/18\">",
"      Uchiyama H, Suda T, Nakamura Y, et al. Alterations in smoking habits are associated with acute eosinophilic pneumonia. Chest 2008; 133:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/19\">",
"      Rhee CK, Min KH, Yim NY, et al. Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J 2013; 41:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/20\">",
"      Kitahara Y, Matsumoto K, Taooka Y, et al. Cigarette smoking-induced acute eosinophilic pneumonia showing tolerance in broncho-alveolar lavage findings. Intern Med 2003; 42:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/21\">",
"      Imokawa S, Sato A, Hayakawa H, et al. Possible involvement of an environmental agent in the development of acute eosinophilic pneumonia. Ann Allergy Asthma Immunol 1996; 76:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/22\">",
"      Glazer CS, Cohen LB, Schwarz MI. Acute eosinophilic pneumonia in AIDS. Chest 2001; 120:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/23\">",
"      McCormick M, Nelson T. Cocaine-induced fatal acute eosinophilic pneumonia: a case report. WMJ 2007; 106:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/24\">",
"      Brander PE, Tukiainen P. Acute eosinophilic pneumonia in a heroin smoker. Eur Respir J 1993; 6:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/25\">",
"      Janz DR, O'Neal HR Jr, Ely EW. Acute eosinophilic pneumonia: A case report and review of the literature. Crit Care Med 2009; 37:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/26\">",
"      Ricker DH, Taylor SR, Gartner JC Jr, Kurland G. Fatal pulmonary aspergillosis presenting as acute eosinophilic pneumonia in a previously healthy child. Chest 1991; 100:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/27\">",
"      Buchheit J, Eid N, Rodgers G Jr, et al. Acute eosinophilic pneumonia with respiratory failure: a new syndrome? Am Rev Respir Dis 1992; 145:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/28\">",
"      Umeki S, Soejima R. Acute and chronic eosinophilic pneumonia: clinical evaluation and the criteria. Intern Med 1992; 31:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/29\">",
"      Umeki S. Reevaluation of eosinophilic pneumonia and its diagnostic criteria. Arch Intern Med 1992; 152:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/30\">",
"      Hayakawa H, Sato A, Toyoshima M, et al. A clinical study of idiopathic eosinophilic pneumonia. Chest 1994; 105:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/31\">",
"      Ogawa H, Fujimura M, Matsuda T, et al. Transient wheeze. Eosinophilic bronchobronchiolitis in acute eosinophilic pneumonia. Chest 1993; 104:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/32\">",
"      Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med 1999; 160:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/33\">",
"      Buddharaju VL, Saraceno JL, Rosen JM, et al. Acute eosinophilic pneumonia associated with shock. Crit Care Med 1999; 27:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/34\">",
"      Miyazaki E, Nureki S, Ono E, et al. Circulating thymus- and activation-regulated chemokine/CCL17 is a useful biomarker for discriminating acute eosinophilic pneumonia from other causes of acute lung injury. Chest 2007; 131:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/35\">",
"      Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/36\">",
"      Abe K, Yanagi S, Imadsu Y, et al. Acute eosinophilic pneumonia with fine nodular shadows. Intern Med 2003; 42:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/37\">",
"      Daimon T, Johkoh T, Sumikawa H, et al. Acute eosinophilic pneumonia: Thin-section CT findings in 29 patients. Eur J Radiol 2008; 65:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/38\">",
"      Cheon JE, Lee KS, Jung GS, et al. Acute eosinophilic pneumonia: radiographic and CT findings in six patients. AJR Am J Roentgenol 1996; 167:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/39\">",
"      Yamaguchi S, Okubo Y, Hossain M, et al. IL-5 predominant in bronchoalveolar lavage fluid and peripheral blood in a patient with acute eosinophilic pneumonia. Intern Med 1995; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/40\">",
"      Allen JN, Liao Z, Wewers MD, et al. Detection of IL-5 and IL-1 receptor antagonist in bronchoalveolar lavage fluid in acute eosinophilic pneumonia. J Allergy Clin Immunol 1996; 97:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/41\">",
"      Okubo Y, Hossain M, Kai R, et al. Adhesion molecules on eosinophils in acute eosinophilic pneumonia. Am J Respir Crit Care Med 1995; 151:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/42\">",
"      Nishigaki Y, Fujiuchi S, Yamazaki Y, et al. Increased vascular endothelial growth factor in acute eosinophilic pneumonia. Eur Respir J 2003; 21:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/43\">",
"      Tazelaar HD, Linz LJ, Colby TV, et al. Acute eosinophilic pneumonia: histopathologic findings in nine patients. Am J Respir Crit Care Med 1997; 155:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/44\">",
"      Swartz J, Stoller JK. Acute eosinophilic pneumonia complicating Coccidioides immitis pneumonia: a case report and literature review. Respiration 2009; 77:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1255/abstract/45\">",
"      Shintani H, Fujimura M, Yasui M, et al. Acute eosinophilic pneumonia caused by cigarette smoking. Intern Med 2000; 39:66.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4374 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-78FC411DA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1255=[""].join("\n");
var outline_f1_14_1255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - High resolution CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4374\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4374|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/21/33107\" title=\"diagnostic image 1A\">",
"      Acute eosinophilic pneumonia PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/43/26303\" title=\"diagnostic image 1B\">",
"      Acute eosinophilic pneumonia CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4374|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/12/11466\" title=\"picture 1\">",
"      Acute eosinophilic pneum Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/50/2858\" title=\"picture 2\">",
"      Acute eosinophilic pneum High",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4374|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/59/9148\" title=\"table 1\">",
"      Eosinophilic pneumonia causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29527?source=related_link\">",
"      Pleural fluid eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=related_link\">",
"      Treatment of chronic eosinophilic pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_14_1256="SCIT: Standard schedules, administration techniques, and monitoring";
var content_f1_14_1256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   SCIT: Standard schedules, administration techniques, and monitoring",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1256/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1256/contributors\">",
"     Harold Nelson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1256/contributors\">",
"     Peter S Creticos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1256/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/14/1256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22754384\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is significant variation in the way subcutaneous immunotherapy (SCIT) is administered around the world, including differences in schedules for injections, safety precautions, training requirements and approaches to documentation. Over the past few decades, professional allergy societies in the United States (US) have made attempts to reduce variations in practice across the US and identify best practices. Practice parameters for SCIT have been published and the practices described in this topic review are consistent with the most recent American guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review conventional schedules for the administration of SCIT, focusing on those used to administer inhalant allergens. Adjustments in schedules in response to adverse effects, injection techniques, safety requirements for facilities at which immunotherapy is given, documentation, and patient monitoring will also be discussed. Accelerated schedules for SCIT (including rush, cluster, and ultrarush) and schedules for Hymenoptera venom immunotherapy are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H11#H11\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Choice of protocol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22754392\">",
"    <span class=\"h1\">",
"     CONVENTIONAL SCHEDULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIT schedules differ in the number of injections per visit, number of visits per week, and the rapidity with which the patient reaches the maintenance dose. Conventional immunotherapy schedules involve one to three injections per week during a build-up phase that lasts a number of weeks, followed by a maintenance phase, during which injections are given every two to four weeks over a period of years.",
"   </p>",
"   <p>",
"    There are faster and slower versions of conventional schedules. The clinician may choose a schedule with a slower (more gradual) build-up for the patient at increased risk for a systemic allergic reaction to the immunotherapy itself. The primary advantage of slower schedules is the reduced risk of systemic allergic reactions. An example of a conservative build-up schedule is provided (",
"    <a class=\"graphic graphic_table graphicRef60803 \" href=\"UTD.htm?34/4/34892\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ]. Slower schedules are appropriate for patients with systemic symptoms during allergen skin testing, those with persistent asthma, those who have already had systemic allergic reactions to previous immunotherapy, or patients with pollen allergy who are building up during high pollen months.",
"   </p>",
"   <p>",
"    Patients without these risk factors usually tolerate a more moderate schedule (",
"    <a class=\"graphic graphic_table graphicRef72555 \" href=\"UTD.htm?41/8/42123\">",
"     table 2",
"    </a>",
"    ). The example provided here was published by Greer Labs and involves 14 fewer injections to reach maintenance than the slower schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/2\">",
"     2",
"    </a>",
"    ]. Advantages of faster schedules include patient and clinician convenience and a shorter time to maintenance and clinical improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868046\">",
"    <span class=\"h2\">",
"     Maintenance phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the maintenance phase, the interval between injections is usually increased from once weekly up to a maximum of once monthly for inhalant allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ]. Some clinicians give maintenance injections every two weeks, while others prefer every three to four weeks. Certain patients receiving maintenance injections at three or four week intervals may report that allergic rhinitis and conjunctivitis symptoms become bothersome the week before their next maintenance injection is due. In this situation, the interval can be shortened to see if better symptom control is achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868053\">",
"    <span class=\"h2\">",
"     Total duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended duration of SCIT is three to five years of maintenance therapy. The data supporting this recommendation and studies addressing the persistence of benefit after discontinuing therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H25#H25\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Duration of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H27#H27\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Persistence of benefit after discontinuation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868375\">",
"    <span class=\"h1\">",
"     ADMINISTRATION OF INJECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues surrounding the administration of SCIT injections include ensuring that the patient is given the correct injection, screening the patient for changes in their health that might alter the safety of immunotherapy, and optimal injection techniques.",
"   </p>",
"   <p>",
"    SCIT can induce anaphylaxis, and the risk factors and incidence of anaphylaxis during immunotherapy are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=see_link&amp;anchor=H3#H3\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Incidence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=see_link&amp;anchor=H12#H12\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Factors associated with fatal and near-fatal anaphylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868806\">",
"    <span class=\"h2\">",
"     Safety precautions at every visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Personnel responsible for administering immunotherapy injections should be trained to perform the following measures methodically at the beginning of each patient visit to increase safety.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relatively common cause of systemic reactions to immunotherapy is the administration of an extract to the wrong patient. For this reason, it is critical to ensure that the allergen immunotherapy extract and dilution are the correct one for the patient before administering the injection. It is advised that patients be asked to provide two identifying pieces of information (eg, name and birth date) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient should be questioned to determine if any local or systemic reactions developed following the previous injection(s).",
"     </li>",
"     <li>",
"      The patient should be questioned to determine if there have been any changes in health status or in medications since the last injection. The onset of pregnancy or the introduction of beta-adrenergic blocker medication should be a cause for reevaluating the continuation of immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consider routinely performing a peak expiratory flow test in patients with asthma. Patients experiencing an asthma exacerbation should not be given an injection that day [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ]. In those who do receive injections, a repeat measurement of peak expiratory flow may be considered prior to discharge from the clinic, even in the absence of symptoms, because some patients are unaware of or ignore changes in lung function.",
"     </li>",
"     <li>",
"      Patients should wait at the site where they received their immunotherapy injection for 30 minutes.",
"     </li>",
"     <li>",
"      Patients should be instructed not to exercise vigorously for at least several hours after receiving an immunotherapy injection. Some clinicians advise patients to avoid vigorous exercise for an hour or two before injections as well. This advice is intended to minimize rapid uptake of the allergen into the systemic circulation, although its utility in preventing systemic reactions has not been formally studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868813\">",
"    <span class=\"h2\">",
"     Injection technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy injections should be given using a calibrated small volume syringe (usually a 1 mL syringe) with a 26- to 27-gauge",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     3/8",
"    </span>",
"    inch non-removable needle [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ]. OSHA has mandated that needles with safety engineered sharp injury protection be used and the Joint Council (JCAAI) recommended in a letter to members dated April 2003 that they comply (",
"    <a class=\"external\" href=\"file://jcaai.org/page/Safe_Needle_Issues/Safe_Needle_Issues\">",
"     file://jcaai.org/page/Safe_Needle_Issues/Safe_Needle_Issues",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The site should be wiped with an alcohol swab before giving the injection.",
"     </li>",
"     <li>",
"      Injections should be given subcutaneously in the lateral or posterior middle portion of the arm [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ]. The subcutaneous tissue has limited blood supply compared to other tissues and allows for slow absorption. Intramuscular injection is avoided because it would lead to more rapid absorption and increased risk of a systemic reaction.",
"     </li>",
"     <li>",
"      The plunger of the syringe may be pulled back slightly to check for blood return before injecting, as an extra safety step. However, a retrospective and prospective study failed to detect blood during 35,000 immunotherapy and immunization injections [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22754801\">",
"    <span class=\"h1\">",
"     TRAINING AND PREPARATION FOR MANAGING SYSTEMIC REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22754406\">",
"    <span class=\"h2\">",
"     Personnel and site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen immunotherapy should be administered in a setting where prompt recognition and treatment of a systemic reaction are optimized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ]. The preferred location of administration of allergen immunotherapy is in the office of the allergy expert who prepared the patient&rsquo;s immunotherapy extract. There should be a clinician or clinician extender (advanced registered nurse practitioner or physician&rsquo;s assistant) appropriately trained in emergency treatment immediately available in the medical facility. These precautions are especially important for patients at high-risk for systemic reactions (highly sensitive, severe symptoms, comorbid conditions, or history of recurrent systemic reactions) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868663\">",
"    <span class=\"h2\">",
"     Equipment and medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment and medications should be immediately available",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stethoscope and sphygmomanometer",
"     </li>",
"     <li>",
"      Aqueous epinephrine 1:1000",
"      <span class=\"nowrap\">",
"       w/v",
"      </span>",
"      (ie, the primary treatment for anaphylaxis)",
"     </li>",
"     <li>",
"      Tourniquet, syringes, large bore (14 gauge) needles and intravenous catheters",
"     </li>",
"     <li>",
"      Equipment to administer oxygen by mask",
"     </li>",
"     <li>",
"      Intravenous fluid set-up",
"     </li>",
"     <li>",
"      Antihistamine for injection (second-line treatment)",
"     </li>",
"     <li>",
"      Glucocorticoids for IM or IV administration (second-line treatment)",
"     </li>",
"     <li>",
"      Equipment to maintain an airway, appropriate for the supervising clinician&rsquo;s expertise and skill",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       Glucagon",
"      </a>",
"      kit for patients on beta-blockers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22754824\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS TO IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions to SCIT consist of local reactions at the site of injection and systemic allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868494\">",
"    <span class=\"h2\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection site reactions consist of redness, pruritus and swelling. A local reaction can range from a few mm in diameter to swelling and erythema that encompasses most of the patient&rsquo;s upper arm. Local reactions to SCIT are common, with 30 to 80 percent of immunotherapy patients experiencing these at least some of the time. Consensus is lacking about what degree of local reaction is expected with SCIT. Some studies have characterized a local reaction as large if it exceeds 2.5 cm in diameter, while others have defined large as bigger than the patient&rsquo;s palm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors may contribute to local reactions. A single site retrospective study found correlations between higher allergen concentration, greater number of allergens per extract, and larger injection volume and higher rates of local reactions smaller than the patient&rsquo;s palm (although not with reactions larger than that) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/5\">",
"     5",
"    </a>",
"    ]. Higher",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    concentrations were not associated with local reactions, although glycerin is known to cause injection site pain, particularly as concentrations approach 50 percent and with higher injection volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868508\">",
"    <span class=\"h3\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local reactions can be reduced by premedication with an antihistamine [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/7\">",
"     7",
"    </a>",
"    ]. Data are lacking on the utility of other interventions, such as the application of cold packs or topical corticosteroid preparations, or dividing the dose between two arms. These measures can be tried for patients with recurrent and bothersome large local reactions.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     Montelukast",
"    </a>",
"    was found in a small randomized pilot study of just 15 patients to be helpful in reducing the severity of local reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/8\">",
"     8",
"    </a>",
"    ], but another small study suggested that montelukast might reduce the effectiveness of SCIT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/9\">",
"     9",
"    </a>",
"    ], so more investigation is required regarding the impact of antileukotriene medications on SCIT.",
"   </p>",
"   <p>",
"    One study found that a local reaction in response to an injection did not predict a repeat local reaction at the next visit, suggesting that dose reduction was not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2962660\">",
"    <span class=\"h2\">",
"     Relationship between local and systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large studies found that local reactions are not immediate harbingers of systemic reactions, and that systemic reactions are not prevented by adjusting the dose in response to large local reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, another study found that systemic reactions were more common in patients who experienced frequent large local reactions (&gt;2.5 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/3\">",
"     3",
"    </a>",
"    ]. One interpretation of this finding is that the tendency to develop large local reactions with SCIT is a marker for a patient who is at higher risk (for undefined reasons) for systemic reactions at some point during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868501\">",
"    <span class=\"h2\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic allergic reactions to SCIT involve organ systems distant from the injection site. Most serious systemic reactions occur within 30 minutes after the injection, therefore a 30-minute waiting period following injection is recommended. These reactions may range in severity from mild rhinitis to fatal cardiopulmonary arrest. A system for classifying the severity of these reactions has been developed and its use is endorsed by the practice parameters (",
"    <a class=\"graphic graphic_table graphicRef54901 \" href=\"UTD.htm?36/28/37325\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of, risk factors for, and measures to prevent systemic reactions to SCIT are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=see_link&amp;anchor=H3#H3\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed and biphasic systemic reactions are also reported following SCIT injections. Because these typically occur after the patient leaves the treatment facility, patients should be warned about these reactions and be instructed what action to take should symptoms occur. Some clinicians provide all or selected patients with autoinjectable epinephrine to use for these late occurring systemic reactions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed systemic reactions, occurring more than 30 minutes after the injection, constitute 27 to 50 percent of all systemic reactions. However, these are usually not severe [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biphasic systemic reactions, defined by resolution of the initial symptoms followed by recurrence of systemic symptoms 2 to 24 hours following the injection, have been reported in up to 23 percent of systemic immunotherapy reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ]. The recurrent symptoms are generally less severe than the initial reaction. Biphasic anaphylaxis from all causes is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19847?source=see_link\">",
"       \"Biphasic and protracted anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22754840\">",
"    <span class=\"h1\">",
"     DOSAGE ADJUSTMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the section that follows, dose and volume are interchangeable when making changes within a given dilution of a patient&rsquo;s extracts. As an example, if a patient is receiving 0.5 mL of a maintenance (1:1",
"    <span class=\"nowrap\">",
"     v/v)",
"    </span>",
"    solution and the dose is reduced by half, this means that 0.25 mL of the 1:1",
"    <span class=\"nowrap\">",
"     v/v",
"    </span>",
"    solution would be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868733\">",
"    <span class=\"h2\">",
"     Following systemic allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is common practice following a systemic reaction to reduce the next injection to the previously tolerated dose and, in cases of very severe reactions, to an even lower dose. However, there are wide variations in the degree to which clinicians reduce doses, and the issue has not been formally studied to identify the best approach. In the case of very severe reactions, the prescribing clinician should review the course of immunotherapy to determine whether the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    assessment justifies continuation of immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ]. There are no established criteria regarding discontinuation of immunotherapy due to systemic reactions and the decision must be made cooperatively with input from both clinician and patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868709\">",
"    <span class=\"h2\">",
"     Missed injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies to provide guidance for the dose adjustments to be made when patients have unscheduled gaps in immunotherapy. An empiric schedule for missed doses during build-up phase from the practice parameters is given in the table (",
"    <a class=\"graphic graphic_table graphicRef59180 \" href=\"UTD.htm?9/55/10107\">",
"     table 4",
"    </a>",
"    ). No similar table has been developed for missed doses during the maintenance phase. The clinician may use the approach suggested, or a similar approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868719\">",
"    <span class=\"h2\">",
"     New vials",
"    </span>",
"    &nbsp;&mdash;&nbsp;When new vials of allergen immunotherapy extract are provided it is customary to reduce the dose by half, even though the same extracts from the same provider are used to compound the new extract and build back up to the dose the patient was previously receiving. This is done because the fresh vials may be more potent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6473761\">",
"    <span class=\"h2\">",
"     New allergen added to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a new allergen extract is introduced, it can be given as a separate injection and built up to the maintenance dose, then added to the allergen immunotherapy extract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868769\">",
"    <span class=\"h2\">",
"     Change in supplier of allergen extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may occasionally be necessary to change suppliers of extracts. There are no published recommendations on how best to transition patients from one brand of extract to another, and the approach described here is that of the author and editors of UpToDate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standardized extracts should be relatively similar among suppliers. We would suggest reducing the dose slightly when changing brands. As an example, if a patient was receiving standardized dust mite mix or cat, the initial dose from the new supplier could be reduced to approximately one-fifth the previous dose, with build-up from there (eg, from 0.5 mL of 1:1 to 0.1 mL of 1:1).",
"     </li>",
"     <li>",
"      Non-standardized pollens have a greater range of variability, so one might reduce the dose by at least one dilution (eg, from 0.5 mL of 1:1 to 0.25 mL or even 0.1 mL of 1:10).",
"     </li>",
"     <li>",
"      Cockroach and fungi extracts can be widely variable (even 100-fold or more), so one might reduce the initial dose by two dilutions or even further (eg, from 0.5 mL if 1:1 to 0.5 mL or even 0.25 mL of 1:100).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical judgment may dictate a more cautious approach in some situations, depending upon a patient&rsquo;s history of systemic reactions to immunotherapy, the season in which the change is being implemented, or other factors.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2963920\">",
"    <span class=\"h2\">",
"     High pollen and mold seasons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some allergists reduce doses during periods of high pollen counts in patients receiving immunotherapy for pollen allergy. However, two large studies including over 600,000 injections did not find a correlation between pollen counts and systemic reactions, although there was a correlation in one study with mean monthly mold counts from August to October [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Until the relationship between environmental exposure and risk of systemic reactions to SCIT is better defined, one option is to decrease the doses slightly in patients who are experiencing significant symptoms due to concomitant high pollen or mold levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868598\">",
"    <span class=\"h1\">",
"     DOCUMENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868605\">",
"    <span class=\"h2\">",
"     Consent form",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should obtain informed consent before initiating allergen immunotherapy. Patients should be informed about the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nature of the treatment and alternatives to treatment: The alternatives to SCIT include medications, as well as continued and strict avoidance of those allergens that can be avoided.",
"     </li>",
"     <li>",
"      Potential risks, including a description of how frequently local reactions and systemic reactions occur and including the possibility of death: The risks of SCIT include the inconvenience and discomfort of local reactions at the sites of injections, which occur in 30 to 80 percent of patients to varying degrees, and the risk of systemic allergic reactions. Systemic allergic reactions occurred at a rate of 0.025 to 0.4 percent of injections, and in 7 percent of treated patients, in two studies of SCIT with aqueous unmodified allergens using conventional build-up regimens with multiple allergens. The rate of death from SCIT, as practiced in North America, has been estimated at one in every two million injections from 1985 to 1989 and 1 in every 2.5 million injections during the subsequent decade. Near fatal systemic reactions have been estimated at one in every one million injections. Anaphylaxis induced by SCIT is reviewed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=see_link&amp;anchor=H3#H3\">",
"       \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Incidence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Costs associated with immunotherapy and who is responsible for these costs: The cost of immunotherapy is obviously dependent upon the care-delivery structure in which it is administered. However, in both European and American studies, SCIT was found to be cost-effective compared to medication-based management, particularly in patients who otherwise require both nasal and pulmonary inhaled medications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H7#H7\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Efficacy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The anticipated duration of immunotherapy: Current recommendations call for three to five years of maintenance injections. Once a patient has reached the end of this period, the patient and clinician should decide together whether to continue or stop treatment. Studies about the persistence of benefit after discontinuing SCIT are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H27#H27\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Persistence of benefit after discontinuation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The anticipated success of immunotherapy: Allergen immunotherapy for inhalant allergens is expected to reduce a patient&rsquo;s allergic symptoms gradually over time [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"       1",
"      </a>",
"      ]. SCIT does not &ldquo;cure&rdquo; a patient of allergies, but rather reduces symptoms and often reduces the need for allergy medications. Different people experience different degrees of benefit, and it is difficult to predict with precision how much an individual patient will improve. Most patients see clear improvement in the first 6 to 12 months of treatment, which continues steadily thereafter as the treatment is continued.",
"     </li>",
"     <li>",
"      Potential preventative effects for allergic asthma: There is evidence that SCIT with inhalant allergens can help prevent the development of allergic asthma in patients who have allergic rhinitis or rhinoconjunctivitis. This is reviewed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H14#H14\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Preventive effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As part of the education of the patient they should be educated about signs and symptoms of systemic reactions and instructed to report symptoms immediately if in the",
"    <span class=\"nowrap\">",
"     office/medical",
"    </span>",
"    facility or to report any delayed systemic reactions to",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868612\">",
"    <span class=\"h2\">",
"     SCIT administration form",
"    </span>",
"    &nbsp;&mdash;&nbsp;The form provides a means to document each injection the patient receives. It should contain the patient&rsquo;s name, date of birth, telephone number and optionally, their picture. The form also specifies the allergen immunotherapy extract contents, dilutions, and expiration dates. For each visit there should be the date of the injection, the arm used, vial and delivered volume in milliliters, any reaction local or systemic, any change in health status or medication, and peak flow (if performed).",
"   </p>",
"   <p>",
"    An example of an allergen immunotherapy administration form is provided (",
"    <a class=\"graphic graphic_form graphicRef61006 \" href=\"UTD.htm?21/48/22275\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If systemic reactions occur, their severity should be recorded. A new grading system for systemic reactions to immunotherapy has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/12\">",
"     12",
"    </a>",
"    ] and is included in the practice parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef54901 \" href=\"UTD.htm?36/28/37325\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868096\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be reevaluated at least every 6 to 12 months while they are receiving immunotherapy. The following issues should be addressed at these visits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is in the build-up phase of immunotherapy, are they progressing as expected towards maintenance?",
"     </li>",
"     <li>",
"      Is the patient consistently keeping appointments?",
"     </li>",
"     <li>",
"      Is the patient experiencing clinical improvement in allergic symptoms?",
"     </li>",
"     <li>",
"      Has the patient experienced any untoward effects from the immunotherapy so far? Does the patient know what the signs and symptoms of a systemic reaction are?",
"     </li>",
"     <li>",
"      Has the patient found it difficult to remain in the office for the required time after each injection?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Periodic visits also give the clinician an opportunity to reinforce safe practices and determine whether adjustments in immunotherapy dosing schedule or allergen content are necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2962538\">",
"    <span class=\"h2\">",
"     Objective testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither laboratory tests nor repeat skin testing is routinely used to monitor a patient&rsquo;s progress during aeroallergen SCIT. However, changes in titrated prick skin tests (using the same extract used for initial testing) have been shown to correlate with clinical response and persistence of remission after discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1256/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, simply repeating skin tests using the standard methods used for diagnosis, with commercial extracts that may or may not be of the same lot, is not sensitive enough to detect the changes induced by immunotherapy in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=see_link\">",
"       \"Patient information: Allergy shots (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1868693\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice parameters for subcutaneous allergen immunotherapy (SCIT) have been published and the practices described in this topic review are consistent with the most recent American guidelines.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional immunotherapy schedules involve one to three injections per week during a build-up phase that lasts a number of weeks, followed by a maintenance phase, during which injections are given every two to four weeks over a period of years. A minimum of three to five years of maintenance therapy is believed optimal for maximal clinical benefit. (See",
"      <a class=\"local\" href=\"#H22754392\">",
"       'Conventional schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At each visit for immunotherapy, it is critical to ensure that the patient receives the correct extracts and doses, is questioned about reactions to past injections, and is screened for interim changes in health status that might increase the risk of a systemic allergic reaction to the injections that day. (See",
"      <a class=\"local\" href=\"#H1868375\">",
"       'Administration of injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCIT should be given in a setting in which personnel are specifically trained in the recognition and management of systemic allergic reactions. In most instances, SCIT is best given in the office of the allergist who prescribed the therapy and with a clinician, a nurse practitioner, or physician&rsquo;s assistant trained in anaphylaxis immediately available. Practice parameters specify the equipment and medications that should be present. (See",
"      <a class=\"local\" href=\"#H22754801\">",
"       'Training and preparation for managing systemic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse reactions to SCIT consist of local reactions at the site of injection and systemic allergic reactions. Local reactions are common and related to several factors, including allergen concentration, greater number of allergens per extract, and larger injection volumes. The preservative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"       glycerin",
"      </a>",
"      can cause pain at the injection site, although it does not appear to cause swelling and erythema. Local reactions are not immediate harbingers of systemic allergic reactions, although patients who suffer systemic reactions tend to have more large local reactions. (See",
"      <a class=\"local\" href=\"#H1868494\">",
"       'Local reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2962660\">",
"       'Relationship between local and systemic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A 30-minute waiting period following SCIT injections is recommended, because more serious systemic reactions begin within this period of time. The incidence of, risk factors for, and measures to prevent systemic reactions to SCIT are reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=see_link&amp;anchor=H3#H3\">",
"       \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Incidence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adjustments to immunotherapy injection schedules may be required for a variety of reasons: missed visits, new vials, high pollen or mold seasons in patients sensitive to those allergens, addition of a new allergen, or change in an extract supplier. It is common practice to reduce the dose of allergen administered following a systemic reaction, although the utility of this intervention in reducing further systemic reactions and the extent to which the dose should be reduced have not been studied. (See",
"      <a class=\"local\" href=\"#H22754840\">",
"       'Dosage adjustments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important components of documentation include informed consent, which includes estimates of potential benefit, as well as a discussion of the risk of severe or fatal systemic reactions, and a longitudinal record of each visit for injections and any reactions that occurred immediately after or between visits. (See",
"      <a class=\"local\" href=\"#H22754840\">",
"       'Dosage adjustments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be followed every 6 to 12 months while receiving immunotherapy to assess compliance, clinical improvement, and adverse reactions. Repeat skin testing and serial laboratory testing are not usually performed. (See",
"      <a class=\"local\" href=\"#H1868096\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/1\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Allergenic extract: Prescription set of serial dilutions. www.greerlabs.com (Accessed on December 06, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/3\">",
"      Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/4\">",
"      Calabria CW, Coop CA, Tankersley MS. The LOCAL Study: Local reactions do not predict local reactions in allergen immunotherapy. J Allergy Clin Immunol 2009; 124:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/5\">",
"      Calabria CW, Coop CA, Tankersley MS. The GILL study: glycerin-induced local reactions in immunotherapy. J Allergy Clin Immunol 2008; 121:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/6\">",
"      Van Metre TE Jr, Rosenberg GL, Vaswani SK, et al. Pain and dermal reaction caused by injected glycerin in immunotherapy solutions. J Allergy Clin Immunol 1996; 97:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/7\">",
"      Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/8\">",
"      W&ouml;hrl S, Gamper S, Hemmer W, et al. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007; 144:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/9\">",
"      Majak P, Rychlik B, Pu��aski L, et al. Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma. J Allergy Clin Immunol 2010; 125:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/10\">",
"      Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000; 106:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/11\">",
"      Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004; 92:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/12\">",
"      Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010; 125:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/13\">",
"      Tinkelman DG, Cole WQ 3rd, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995; 95:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/14\">",
"      Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/15\">",
"      Bousquet J, Maasch H, Martinot B, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1256/abstract/16\">",
"      Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51:430.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15757 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1256=[""].join("\n");
var outline_f1_14_1256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1868693\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22754384\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22754392\">",
"      CONVENTIONAL SCHEDULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868046\">",
"      Maintenance phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868053\">",
"      Total duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1868375\">",
"      ADMINISTRATION OF INJECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868806\">",
"      Safety precautions at every visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868813\">",
"      Injection technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22754801\">",
"      TRAINING AND PREPARATION FOR MANAGING SYSTEMIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22754406\">",
"      Personnel and site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868663\">",
"      Equipment and medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22754824\">",
"      ADVERSE REACTIONS TO IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868494\">",
"      Local reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1868508\">",
"      - Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2962660\">",
"      Relationship between local and systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868501\">",
"      Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22754840\">",
"      DOSAGE ADJUSTMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868733\">",
"      Following systemic allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868709\">",
"      Missed injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868719\">",
"      New vials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6473761\">",
"      New allergen added to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868769\">",
"      Change in supplier of allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2963920\">",
"      High pollen and mold seasons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1868598\">",
"      DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868605\">",
"      Consent form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1868612\">",
"      SCIT administration form",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1868096\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2962538\">",
"      Objective testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1868693\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/15757\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15757|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?21/48/22275\" title=\"form 1\">",
"      SCIT administration form",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15757|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/4/34892\" title=\"table 1\">",
"      Conservative schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/8/42123\" title=\"table 2\">",
"      Moderate schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/28/37325\" title=\"table 3\">",
"      Grading system for systemic reactions to immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/55/10107\" title=\"table 4\">",
"      Adjustments for missed appointments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=related_link\">",
"      Anaphylaxis induced by subcutaneous allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19847?source=related_link\">",
"      Biphasic and protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/5/42066?source=related_link\">",
"      Patient information: Allergy shots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_14_1257="Primary focal hyperhidrosis";
var content_f1_14_1257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary focal hyperhidrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1257/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1257/contributors\">",
"     C Christopher Smith, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1257/contributors\">",
"     David Pariser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1257/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1257/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1257/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1257/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/14/1257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperhidrosis (excessive sweating) is a common condition rarely due to significant underlying pathology that may have serious social, emotional, and professional consequences.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of primary focal hyperhidrosis is reviewed here. Night sweats and menopausal hot flashes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=see_link\">",
"     \"Approach to the patient with night sweats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperhidrosis is the secretion of sweat in amounts greater than physiologically needed for thermoregulation. It is most commonly a chronic idiopathic (primary) condition; however, secondary medical conditions or medications should be excluded. Idiopathic hyperhidrosis localized to certain areas of the body is called primary focal hyperhidrosis. Primary focal hyperhidrosis usually affects the axillae, palms, and soles.",
"   </p>",
"   <p>",
"    A consensus panel suggested the following diagnostic criteria for primary focal hyperhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal, visible, excessive sweating of at least six months duration without apparent cause",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    plus at least two of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral and relatively symmetric",
"     </li>",
"     <li>",
"      Impairs daily activities",
"     </li>",
"     <li>",
"      At least one episode per week",
"     </li>",
"     <li>",
"      Onset before age 25",
"     </li>",
"     <li>",
"      Family history of idiopathic hyperhidrosis",
"     </li>",
"     <li>",
"      Focal sweating stops during sleep",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary focal hyperhidrosis generally develop symptoms in childhood or adolescence that persist throughout life. Patients have focal symptoms most often localized to the palms, soles, and axillae [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Less commonly, primary focal hyperhidrosis may affect the scalp and face, or other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/4\">",
"     4",
"    </a>",
"    ]. While primary focal hyperhidrosis is made worse by heat or emotional stimuli, it is not considered a psychological disorder.",
"   </p>",
"   <p>",
"    Patients with axillary hyperhidrosis report skin maceration and staining of clothes. Palmar hyperhidrosis often leads to a fear of shaking hands and soiling of papers, and patients may have difficulty with work or recreational tasks that require a dry grip. Patients report that hyperhidrosis often results in social problems on both a private and professional level.",
"   </p>",
"   <p>",
"    Hyperhidrosis is associated with an increased incidence of other cutaneous disorders. In a retrospective case-control study involving 387 patients with primary focal hyperhidrosis, patients with hyperhidrosis were more likely to suffer from dermatophytosis, pitted keratolysis, and viral warts at the sites of hyperhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, atopic dermatitis and other eczematous dermatitides were present at a greater frequency in subjects with hyperhidrosis. The reason for this association is unknown; one theory is that hyperhidrosis is an exacerbating factor for dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperhidrosis prevalence estimates range from 1 to 3 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of patients with primary palmar hyperhidrosis who had been treated with thoracoscopic sympathectomy found that 49 of 58 patients and none of 20 controls reported a family history of hyperhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/7\">",
"     7",
"    </a>",
"    ] suggests a genetic component to the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sweating assists thermoregulation, skin hydration, and fluid and electrolyte balance. Three types of sweat glands, eccrine and apocrine, and apoeccrine glands have been described in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/8\">",
"     8",
"    </a>",
"    ]. Eccrine sweat glands are responsible for hyperhidrosis, although apoeccrine glands might play a role in axillary hyperhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary function of eccrine sweat glands is thermoregulation, with cooling resulting from evaporation of eccrine sweat. Eccrine sweat glands are located throughout the body, but they are found in greatest quantity in the palms, soles, and (to a lesser degree) axillae. Sweating on the face, chest, and back is generally due to heat stimuli, while sweating of the palms and soles is due to emotional stress. The axillae have eccrine, apocrine, and apoeccrine glands. Thermal sweating can occur throughout the day, but emotional sweating (palms, soles, and to some degree axillae) stops while sleeping [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eccrine glands are innervated by the sympathetic nervous system but utilize acetylcholine as the primary neurotransmitter. Thermal and emotional sweating are controlled by different regions of the brain. Thermal sweating is controlled by the hypothalamus via the thermosensitive preoptic sweat center, while emotional sweating is regulated by the cerebral cortex. A sympathetic signal is carried to endocrine glands via cholinergic autonomic neurons. In patients with primary focal hyperhidrosis, the sweat glands are usually histologically and functionally normal. Rather, the cause of hyperhidrosis appears to be an abnormal or exaggerated central response to normal emotional stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary focal hyperhidrosis generally have hyperhidrosis involving the face, palms, soles, and axillae. Generalized sweating suggests an etiology other than primary focal hyperhidrosis.",
"   </p>",
"   <p>",
"    The most common cause of generalized sweating is excessive heat. Generalized hyperhidrosis can be due to systemic diseases or medications. Unlike primary focal hyperhidrosis, patients with generalized, secondary hyperhidrosis usually present as adults and report sweating that occurs both while awake and sleeping. A history of generalized hyperhidrosis requires a careful evaluation for systemic causes. The differential diagnosis for generalized hyperhidrosis is similar to the differential diagnosis of night sweats. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=see_link\">",
"     \"Approach to the patient with night sweats\"",
"    </a>",
"    .) One should evaluate for signs and symptoms of an infectious cause such as tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/12\">",
"     12",
"    </a>",
"    ], HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/13\">",
"     13",
"    </a>",
"    ], or endocarditis; a malignant etiology such as lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]; or an endocrinopathy such as carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/16\">",
"     16",
"    </a>",
"    ], pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/17\">",
"     17",
"    </a>",
"    ], or hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications should be carefully reviewed as many can cause generalized sweating (",
"    <a class=\"graphic graphic_table graphicRef56351 \" href=\"UTD.htm?33/32/34317\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While menopause is a common cause of excessive sweating, clinicians should perform a careful history and examination before concluding that excessive sweating in a woman of perimenopausal age is due to hot flashes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of excessive sweating include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with previous spinal cord injuries may occasionally develop episodes of diffuse sweating long after their injury. These sweating episodes can be due to an autonomic dysreflexia, orthostatic hypotension, or a post-traumatic syringomyelia. Hyperhidrosis attributed to autonomic dysreflexia is caused by an exaggerated autonomic response to normal stimuli such as bowel and bladder distention or skin irritation. In addition to sweating of the face, neck, and trunk, patients generally have flushing of the face and a throbbing headache. Their spinal cord lesion is usually at or above the sixth thoracic level. A post-traumatic syringomyelia may occur months to years after the development of paraplegia from a spinal cord injury of any level. The syrinx may develop above or below the level of the transection and may be associated with progressive numbness of the hyperhidrotic areas [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gustatory sweating (mild sweating around the lips, nose, and forehead) occurs normally with the consumption of hot, spicy foods. However, pathologic gustatory sweating may be caused by sympathetic nerve damage, either due to invasion (such as a Pancoast tumor), or by sympathectomy (see below). It can also be due to a diabetic neuropathy, herpes zoster of the preauricular region, or misdirection of autonomic nerve fibers following parotid surgery (Frey's syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary focal hyperhidrosis can lead to significant social and employment distress. While many effective therapies exist, they are often associated with difficult side effects. It is important to understand the patient's goals and expectations and to carefully counsel the patient on available treatments, as well as their limitations and complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most commercially available over-the-counter antiperspirants contain a low-dose metal salt (usually aluminum) that physically obstructs the opening of sweat gland ducts. These over-the-counter products are only successful in treating patients with very mild symptoms.",
"   </p>",
"   <p>",
"    In patients who do not respond to over-the-counter antiperspirants, prescription strength antiperspirants such as 20 percent aluminum chloride in ethanol (Drysol) or 6.25 percent aluminum tetrachloride (Xerac) may provide adequate therapy for patients with mild to moderate axillary, palmar, or plantar hyperhidrosis (though they are generally more successful in treatment of axillary than palmar or plantar hyperhidrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These antiperspirants are thought to work by mechanically obstructing the eccrine sweat gland ducts or by causing atrophy of the secretory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prescription strength antiperspirants should be applied nightly until improvement is noted; significant improvement may be noted within one week. The interval between applications can then be gradually lengthened, with once weekly applications typically needed for maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, treatment with strong antiperspirants is often limited by skin irritation (especially in the axillary region). To reduce the risk of irritation, these products should be applied to dry skin between episodes of sweating. Ideally, it should be applied at bedtime when hyperhidrosis is at a minimum and washed off in the morning [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/22\">",
"     22",
"    </a>",
"    ]. Others have recommended using a hair dryer to quickly dry the application, or to use baking soda powder in the morning to neutralize any remaining aluminum chloride [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/11\">",
"     11",
"    </a>",
"    ]. Low potency corticosteroid creams (such as 2.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    cream) can help alleviate the axillary irritation that frequently occurs.",
"   </p>",
"   <p>",
"    A small trial found that topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    2 percent reduced forehead sweat production in patients with primary craniofacial or secondary gustatory hyperhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/23\">",
"     23",
"    </a>",
"    ]. Topical glycopyrrolate is only available through compounding pharmacies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although systemic therapies (anticholinergics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , beta-blockers, and benzodiazepines) can be effective for primary focal hyperhidrosis, concern regarding the potential adverse effects of systemic agents has inhibited the routine use of these therapies. Topical agents remain the initial treatment of choice for primary focal hyperhidrosis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Topical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common anticholinergic agents prescribed for primary focal hyperhidrosis are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Glycopyrrolate is utilized more frequently than oxybutynin. However, only oxybutynin has been evaluated in a randomized trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"       Glycopyrrolate",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      The use of oral glycopyrrolate for hyperhidrosis is supported by retrospective case series [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. In one retrospective series in which 45 patients with primary hyperhidrosis (axillary, palmoplantar, generalized, or craniofacial) received treatment with glycopyrrolate alone (11 patients) or in combination with local therapies (34 patients), 67 percent of patients reported symptomatic improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, a retrospective study of 31 children with hyperhidrosis (mean age of 15 years) found that 71 percent achieved major improvement in symptoms during treatment with glycopyrrolate (with or without concomitant topical aluminum chloride) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/28\">",
"       28",
"      </a>",
"      ]. The children in this study were treated with an average total dose of 2 mg of glycopyrrolate per day. Typical doses for adults range from 1 to 2 mg once or twice daily (ie, 1 to 4 mg per day).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"       Oxybutynin",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      The efficacy of oxybutynin for hyperhidrosis was documented in a six-week randomized trial of 50 patients with palmar or axillary hyperhidrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/29\">",
"       29",
"      </a>",
"      ]. At six weeks, great or moderate improvement in symptoms occurred in 48 and 26 percent of patients treated with oxybutynin (2.5 mg per day for one week, 2.5 mg twice daily for two weeks, and 5 mg twice daily for three weeks), respectively. In contrast, great or moderate improvement was reported by 0 and 27 percent of patients treated with placebo, respectively. Uncontrolled studies performed by the same authors also support the efficacy of oxybutynin for facial, palmar, and axillary hyperhidrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential adverse effects of anticholinergic agents include dry mouth (most common), blurred vision, headache, and urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. Although the side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    are often tolerable, discontinuation of glycopyrrolate may be necessary in up to one-third of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/25\">",
"     25",
"    </a>",
"    ]. Additional studies are necessary to confirm the long term efficacy and safety of anticholinergic drugs when utilized for this indication. Contraindications to these therapies are reviewed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     \"Glycopyrrolate (glycopyrronium): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     \"Oxybutynin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, other drugs have been employed for the treatment of hyperhidrosis. Evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , an alpha-2 adrenergic agonist that reduces sympathetic outflow, for hyperhidrosis is limited to case reports and a small retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/26,33,34\">",
"     26,33,34",
"    </a>",
"    ]. Reduced blood pressure is a potential adverse effect of this agent.",
"   </p>",
"   <p>",
"    In patients with hyperhidrosis related to specific emotional events, beta-blockers or benzodiazepines may be useful in reducing the emotional stimulus that leads to the excessive sweating [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/22,35,36\">",
"     22,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Iontophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iontophoresis is the introduction of ionized substances through intact skin by the application of direct current (also called electromotive drug administration or transdermal electromotive drug administration). The exact mechanism of action is unclear, but it is thought to temporarily block sweat glands [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/11,22\">",
"     11,22",
"    </a>",
"    ]. Iontophoresis for hyperhidrosis is typically performed with tap water, and equipment is available for home use.",
"   </p>",
"   <p>",
"    Iontophoresis is most often used for palmar or plantar hyperhidrosis, but a special axillary electrode can be used to treat axillary hyperhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/37\">",
"     37",
"    </a>",
"    ]. Still, treatment of the axillae is often less effective due to the difficulty of obtaining uniform contact of the electrode with the axillary skin. Although there are only limited data from randomized trials, iontophoresis appears to alleviate symptoms in approximately 85 percent of patients with palmar or plantar hyperhidrosis and is safe and simple to perform [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. If tap water iontophoresis is ineffective, some authors recommend adding anticholinergic agents to the treatment trays [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there are few side effects other than dry, cracked hands (which can be relieved with moisturizers), the biggest issue for patients with this treatment modality is generally the time required to perform the treatments. Initial treatment is generally 20 to 30 minutes per day; however, the frequency of treatments can often be reduced after only 10 to 15 treatments. While some studies have found that a reduction in sweating can be maintained with therapy every two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/38\">",
"     38",
"    </a>",
"    ], some patients find that shorter duration treatments three times a week are required for maintenance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin A (BTX-A) blocks the release of neuronal acetylcholine from the presynaptic junction of both neuromuscular and cholinergic autonomic neurons. Botulinum toxin's effect at the neuromuscular junction has been used to treat conditions such as dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/42\">",
"     42",
"    </a>",
"    ] and achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/43\">",
"     43",
"    </a>",
"    ]. By blocking the release of acetylcholine, botulinum toxin can also temporarily reduce sweat production. Most studies have used one of two preparations of BTX-A: onabotulinumtoxinA (Botox) or abobotulinumtoxinA (Dysport). These two preparations have different dosing; 1 unit of onabotulinumtoxinA is equal to approximately 3 units of abobotulinumtoxinA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/44\">",
"     44",
"    </a>",
"    ]. US Food and Drug Administration (FDA) approval for botulinum toxin for hyperhidrosis is limited to onabotulinumtoxinA for axillary hyperhidrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Axillary hyperhidrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown BTX-A to be particularly effective in the treatment of axillary hyperhidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/44-50\">",
"     44-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial involving 320 patients with bilateral primary axillary hyperhidrosis, response rates after four weeks were significantly higher with onabotulinumtoxinA, 50 units per axilla, than placebo (94 versus 36 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/47\">",
"       47",
"      </a>",
"      ]. After 16 weeks, 82 percent of the onabotulinumtoxinA group still had an effective response compared with 21 percent of the placebo group. Adverse events were similar in the two groups; however, more patients treated with onabotulinumtoxinA reported an increase in non-axillary sweating (5 versus 0 percent).",
"     </li>",
"     <li>",
"      In a randomized trial involving 145 patients with primary axillary hyperhidrosis unresponsive to topical therapy with aluminum chloride, patients were injected with 200 units of abobotulinumtoxinA in one axilla and placebo in the other; after two weeks, the treatments were revealed, and the axilla that had been treated with placebo was injected with 100 units of abobotulinumtoxinA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/44\">",
"       44",
"      </a>",
"      ]. Two weeks after the initial injection, the rate of sweat production was significantly less on the side treated with abobotulinumtoxinA (24 versus 144",
"      <span class=\"nowrap\">",
"       mg/min).",
"      </span>",
"      Two weeks after the injection with 100 U, the rate of sweat production decreased from 144 to 32",
"      <span class=\"nowrap\">",
"       mg/min.",
"      </span>",
"      The mean reduction in sweating was greater with the 200 units injection (81.4 versus 76.5 percent). Twenty-six weeks after the initial injection, the rates of sweat production were still significantly lower than baseline in both axillae. No major adverse events were noted, and 92.4 percent were satisfied or completely satisfied with their results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the above study found a statistically greater reduction in sweating with 200 units of abobotulinumtoxinA, it is not clear that this difference is clinically important. A study of 43 patients found no difference in the degree or duration of reduction in sweating with 100 or 200 units of abobotulinumtoxinA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/51\">",
"     51",
"    </a>",
"    ]. After 48 weeks, sweat production was the same in both groups and had returned nearly to baseline. A second injection at that point with either 100 units or 200 units of abobotulinumtoxinA again produced identical reductions in sweating; 48 weeks after the second injection sweat production was significantly lower than 48 weeks after the first injection.",
"   </p>",
"   <p>",
"    Other studies have also shown continued efficacy for hyperhidrosis after several injections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/46\">",
"     46",
"    </a>",
"    ]. However, patients treated with BTX-A can develop antibodies, and when BTX-A has been used in other settings this has occasionally limited therapeutic effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Palmar hyperhidrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of BTX-A in the treatment of palmar hyperhidrosis has been demonstrated in several trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial in 19 patients with palmar hyperhidrosis, placebo was given in one hand and botulinum toxin in the other [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/55\">",
"       55",
"      </a>",
"      ]. After four weeks, among the 17 patients not lost to follow-up, all rated the BTX-A injections a success, while only 12 percent rated the placebo injections a success. One patient had transient thenar weakness.",
"     </li>",
"     <li>",
"      In a study of 20 patients with palmar hyperhidrosis who had not responded to topical and iontophoresis therapy, all developed anhidrosis by two weeks after therapy, with a continued reduction in sweating at least 12 months after therapy in all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain during injections is one of the most common complaints with this therapy. Whether being used for treatment of palmar or axillary hyperhidrosis, the application of botulinum toxin requires multiple, small-dose injections of the toxin. Multiple injections into sensitive areas such as the palms and soles are particularly painful for patients. In the study mentioned above, the 20 patients with palmar hyperhidrosis received an average of 26 injections (versus an average of 10 injections for axillary hyperhidrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryoanalgesia (refrigerant sprays or ice packs) or vibration anesthesia may be of some benefit in decreasing pain associated with injection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]. Topical anesthetics have also been used in attempt to reduce pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/64\">",
"     64",
"    </a>",
"    ], but may be poorly effective on the palms and soles where the thick stratum corneum may reduce drug penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One additional complication commonly reported with use for palmar hyperhidrosis is the development of temporary weakness in the muscles of the thenar eminence. In the above study, 21 percent reported weakness that lasted an average of three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many years axillary hyperhidrosis was surgically treated with subcutaneous curettage or excision of the skin containing these eccrine glands. However, this procedure has a significant failure rate and is associated with permanent scarring and the risk of restricted arm movement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/68\">",
"     68",
"    </a>",
"    ]. Newer surgical techniques for excising axillary eccrine and apocrine sweat glands, such as minimally invasive suction curettage, may have improved outcomes and decreased morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/69\">",
"     69",
"    </a>",
"    ], however larger long-term studies are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used surgical technique for treatment of upper extremity hyperhidrosis involves the interruption of the upper thoracic sympathetic chain (usually from the second to fourth thoracic ganglia). Numerous studies have shown endoscopic transthoracic sympathectomies (ETS) to be effective, but the potential for adverse effects, particularly the development of compensatory hyperhidrosis, precludes the use of ETS as first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/71-75\">",
"     71-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 850 patients with upper extremity hyperhidrosis was treated with bilateral endoscopic transthoracic sympathectomies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/71\">",
"       71",
"      </a>",
"      ]. After a median follow-up of 31 months, 98 percent of patients reported satisfactory results, with only 2 percent developing recurrent symptoms. There were no life-threatening complications. Horner's syndrome occurred in three cases. Compensatory sweating, primarily of the trunk, occurred in 55 percent of patients, but only 2 percent considered this to be as bothersome as their original hyperhidrosis symptoms.",
"     </li>",
"     <li>",
"      In a review of 480 sympathectomies, there were no major complications requiring surgical reintervention and no postoperative deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/73\">",
"       73",
"      </a>",
"      ]. Initially, 95.5 percent were satisfied with the results of surgery. However, over time satisfaction waned; after a mean follow-up of 14.6 years, 66.7 percent were satisfied and 26.7 percent were partially satisfied despite a recurrence rate of only 1.5 percent. Patients with axillary hyperhidrosis without palmar involvement were the least satisfied. Compensatory and gustatory sweating, which occurred in 67.4 percent and 50.7 percent of patients, respectively were the most frequently stated reasons for dissatisfaction.",
"     </li>",
"     <li>",
"      A study evaluating long-term results (median follow-up 3.8 years) in 125 patients who underwent ETS for treatment of upper limb hyperhidrosis found a much higher recurrence rate for axillary than palmar symptoms (65 versus 6.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/72\">",
"       72",
"      </a>",
"      ]. Eighty-six percent developed compensatory sweating; however, 61 percent of these patients considered this only a minor disturbance, and only 6.3 percent of patients reported regret in having the surgery. Horner's syndrome occurred in three patients.",
"     </li>",
"     <li>",
"      A study evaluating the severity of compensatory sweating in 158 patients who underwent bilateral sympathectomy received questionnaires back from 148 patients (94 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/76\">",
"       76",
"      </a>",
"      ]. Compensatory sweating occurred in 89 percent of patients and was severe enough that patients often needed to change clothes during the day in 35 percent; 16 percent regretted having the surgery. Patients who had facial hyperhidrosis or blushing underwent surgery at the second thoracic ganglia; those who had palmar hyperhidrosis underwent surgery at the second and third thoracic ganglia; and those who had axillary hyperhidrosis underwent surgery at the second, third, and fourth thoracic ganglia. Compensatory sweating was more severe in the last group. The study could not distinguish whether this represented more severe compensatory sweating after more extensive sympathectomy or after sympathectomy performed in patients with axillary hyperhidrosis.",
"     </li>",
"     <li>",
"      A retrospective review of 234 records of patients treated with ETS examined associations between the level of the sympathectomy and outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/77\">",
"       77",
"      </a>",
"      ]. Although ETS for palmar hyperhidrosis is most commonly performed at a T2 or T3 level, similar efficacy was seen with T4-level ETS. Patients treated at a T4 level had less compensatory sweating than those with higher sympathectomies.",
"     </li>",
"     <li>",
"      On a follow-up questionnaire in 180 patients who had undergone ETS (T2 or T2-3) for isolated facial blushing, compensatory and gustatory sweating were reported by 88 and 30 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/78\">",
"       78",
"      </a>",
"      ]. Of those with compensatory sweating, in one-fourth it was severe enough to require changing clothes during the day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thoracic sympathetic clipping is an alternative to permanent severing of the sympathetic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. The results of a prospective study of 727 patients treated with thorascopic sympathetic clipping for hyperhidrosis or facial flushing support the efficacy of the procedure for hyperhidrosis and suggest that some patients who develop postoperative compensatory sweating benefit from reversal of the procedure via clip removal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/81\">",
"     81",
"    </a>",
"    ]. In the study, 15 out of 31 patients (48 percent) followed after a reversal procedure reported a substantial reduction in compensatory sweating. Additional studies are necessary to evaluate efficacy, safety, and reversibility of sympathetic clipping in hyperhidrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536570\">",
"    <span class=\"h2\">",
"     Microwave energy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies suggest that microwave energy can be utilized to destroy eccrine glands and relieve hyperhidrosis in the axilla [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. In a randomized trial of 120 adults with primary axillary hyperhidrosis who were given one to three treatments with a microwave energy device (n = 81) or a sham device (n = 39), patients treated with the microwave device were more likely to notice a subjective reduction in the severity of axillary hyperhidrosis 30 days after treatment than patients in the sham treatment group (89 versus 54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1257/abstract/85\">",
"     85",
"    </a>",
"    ]. The difference in favor of active treatment remained statistically significant for up to six months.",
"   </p>",
"   <p>",
"    In addition, more patients in the active group achieved at least a 50 or 75 percent reduction in a gravimetric measurement of sweat production through six months after treatment. However, this difference was only statistically significant for patients who achieved &ge;75 percent improvement at the 30 day time point (62 versus 39 percent).",
"   </p>",
"   <p>",
"    The most common side effects of treatment were altered skin sensation (median duration 25 days, range 4 to 225 days), discomfort, and other local reactions. Additional studies are necessary to determine the role of microwave energy devices in the treatment of hyperhidrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with primary focal hyperhidrosis typically have excessive sweating of the palms, soles, and axillae and can suffer significant psychological, social, educational, and occupational consequences.",
"   </p>",
"   <p>",
"    Patients with generalized hyperhidrosis not limited to the palms, soles, and axillae are likely to have hyperhidrosis secondary to medications or a systemic illness, and the evaluation is similar to that done for night sweats. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=see_link\">",
"     \"Approach to the patient with night sweats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When choosing treatments for primary focal hyperhidrosis, the patient's goals in therapy should be understood, and the side effects associated with each therapy should be carefully discussed. Conservative measures should be tried before progressing to more invasive treatments. The severity and location of hyperhidrosis helps guide the choice of therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild to moderately severe axillary, palmar, or plantar hyperhidrosis should initially be treated with topical agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/48/28418?source=see_link\">",
"       aluminum chloride hexahydrate",
"      </a>",
"      in alcohol. Skin irritation is common but may be managed by applying the preparation on dry skin at bedtime and washing it off in the morning; irritated skin can also be treated with 2.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      cream. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Topical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic therapies such as beta-blockers or benzodiazepines may be useful in treating symptoms directly related to emotional stress. Anticholinergic drugs and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      can be helpful for hyperhidrosis, but the use of these agents may be complicated by side effects. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palmar and plantar hyperhidrosis can be treated effectively with iontophoresis, but treatments can be time consuming. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Iontophoresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Axillary hyperhidrosis can be effectively treated with botulinum toxin (BTX). Palmar and plantar hyperhidrosis can also be treated with BTX, but the injections are quite painful on the hands and feet, and a significant percentage of patients develop temporary local muscle weakness. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Botulinum toxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with palmar hyperhidrosis who fail topical therapies and iontophoresis, and who do not tolerate or get relief from BTX, can be treated effectively with endoscopic thoracic sympathectomy (ETS) Side effects, especially compensatory hyperhidrosis in other parts of the body, which may reduce long-term patient satisfaction with this procedure. Patients should be informed of the potential for this adverse effect. ETS can also be used for axillary hyperhidrosis, but the relapse rate is high. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While ETS has also been used for facial hyperhidrosis, rates of compensatory and gustatory hyperhidrosis after the procedure appear to be very high. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/1\">",
"      Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004; 51:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/2\">",
"      Moran KT, Brady MP. Surgical management of primary hyperhidrosis. Br J Surg 1991; 78:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/3\">",
"      Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004; 51:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/4\">",
"      Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol 2009; 61:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/5\">",
"      Adar R, Kurchin A, Zweig A, Mozes M. Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg 1977; 186:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/6\">",
"      Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol 1999; 38:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/7\">",
"      Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg 2002; 35:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/8\">",
"      Scrivener Y, Cribier B. [Morphology of sweat glands]. Morphologie 2002; 86:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/9\">",
"      Lonsdale-Eccles A, Leonard N, Lawrence C. Axillary hyperhidrosis: eccrine or apocrine? Clin Exp Dermatol 2003; 28:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/10\">",
"      Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. I. Normal sweat gland function. J Am Acad Dermatol 1989; 20:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/11\">",
"      Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. II. Disorders of sweat gland function. J Am Acad Dermatol 1989; 20:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/12\">",
"      Van den Brande P, Vijgen J, Demedts M. Clinical spectrum of pulmonary tuberculosis in older patients: comparison with younger patients. J Gerontol 1991; 46:M204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/13\">",
"      Bollinger RC, Brookmeyer RS, Mehendale SM, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 1997; 278:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/14\">",
"      Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/15\">",
"      Gobbi PG, Pieresca C, Ricciardi L, et al. Night sweats in Hodgkin's disease. A manifestation of preceding minor febrile pulses. Cancer 1990; 65:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/16\">",
"      Spaulding SW, Lippes H. Hyperthyroidism. Causes, clinical features, and diagnosis. Med Clin North Am 1985; 69:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/17\">",
"      Vinik AI, McLeod MK, Fig LM, et al. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 1989; 18:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/18\">",
"      Trop CS, Bennett CJ. The evaluation of autonomic dysreflexia. Semin Urol 1992; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/19\">",
"      Scholes KT, Crow KD, Ellis JP, et al. Axillary hyperhidrosis treated with alcoholic solution of aluminium chloride hexahydrate. Br Med J 1978; 2:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/20\">",
"      Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol 1990; 29:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/21\">",
"      H&ouml;lzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminium chloride hexahydrate solution. Br J Dermatol 1984; 110:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/22\">",
"      Stolman LP. Treatment of hyperhidrosis. Dermatol Clin 1998; 16:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/23\">",
"      Kim WO, Kil HK, Yoon KB, Yoon DM. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 2008; 158:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/24\">",
"      Tupker RA, Harmsze AM, Deneer VH. Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol 2006; 142:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/25\">",
"      Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol 2007; 157:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/26\">",
"      Walling HW. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol 2012; 66:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/27\">",
"      Lee HH, Kim do W, Kim do W, Kim C. Efficacy of glycopyrrolate in primary hyperhidrosis patients. Korean J Pain 2012; 25:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/28\">",
"      Paller AS, Shah PR, Silverio AM, et al. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol 2012; 67:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/29\">",
"      Wolosker N, de Campos JR, Kauffman P, Puech-Le&atilde;o P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg 2012; 55:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/30\">",
"      Wolosker N, de Campos JR, Kauffman P, et al. The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg 2011; 25:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/31\">",
"      Wolosker N, Campos JR, Kauffman P, et al. The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol 2011; 86:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/32\">",
"      Wolosker N, de Campos JR, Kauffman P, et al. An alternative to treat palmar hyperhidrosis: use of oxybutynin. Clin Auton Res 2011; 21:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/33\">",
"      Kuritzky A, Hering R, Goldhammer G, Bechar M. Clonidine treatment in paroxysmal localized hyperhidrosis. Arch Neurol 1984; 41:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/34\">",
"      Torch EM. Remission of facial and scalp hyperhidrosis with clonidine hydrochloride and topical aluminum chloride. South Med J 2000; 93:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/35\">",
"      Mack GW, Shannon LM, Nadel ER. Influence of beta-adrenergic blockade on the control of sweating in humans. J Appl Physiol 1986; 61:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/36\">",
"      Quraishy MS, Giddings AE. Treating hyperhidrosis. BMJ 1993; 306:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/37\">",
"      Reinauer S, Neusser A, Schauf G, H&ouml;lzle E. Iontophoresis with alternating current and direct current offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. Br J Dermatol 1993; 129:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/38\">",
"      Dahl JC, Glent-Madsen L. Treatment of hyperhidrosis manuum by tap water iontophoresis. Acta Derm Venereol 1989; 69:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/39\">",
"      Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol 1987; 123:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/40\">",
"      Levit F. Simple device for treatment of hyperhidrosis by iontophoresis. Arch Dermatol 1968; 98:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/41\">",
"      H&ouml;lzle E, Alberti N. Long-term efficacy and side effects of tap water iontophoresis of palmoplantar hyperhidrosis--the usefulness of home therapy. Dermatologica 1987; 175:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/42\">",
"      Hallett M. One man's poison--clinical applications of botulinum toxin. N Engl J Med 1999; 341:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/43\">",
"      Pasricha PJ, Ravich WJ, Hendrix TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 332:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/44\">",
"      Heckmann M, Ceballos-Baumann AO, Plewig G, Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001; 344:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/45\">",
"      Naumann M, Lowe NJ, Kumar CR, et al. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003; 139:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/46\">",
"      Schnider P, Moraru E, Kittler H, et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol 2001; 145:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/47\">",
"      Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001; 323:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/48\">",
"      Wollina U, Karamfilov T, Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 2002; 46:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/49\">",
"      Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox. Dermatol Surg 1998; 24:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/50\">",
"      Naumann M, Hofmann U, Bergmann I, et al. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998; 134:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/51\">",
"      Heckmann M, Plewig G, Hyperhidrosis Study Group. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 2005; 141:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/52\">",
"      Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004; 19 Suppl 8:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/53\">",
"      Dressler D, Wohlfahrt K, Meyer-Rogge E, et al. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 2010; 36 Suppl 4:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/54\">",
"      Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000; 42:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/55\">",
"      Lowe NJ, Yamauchi PS, Lask GP, et al. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002; 28:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/56\">",
"      Odderson IR. Hyperhidrosis treated by botulinum A exotoxin. Dermatol Surg 1998; 24:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/57\">",
"      Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997; 136:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/58\">",
"      Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998; 38:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/59\">",
"      Kontochristopoulos G, Gregoriou S, Zakopoulou N, Rigopoulos D. Cryoanalgesia with dichlorotetrafluoroethane spray versus ice packs in patients treated with botulinum toxin-a for palmar hyperhidrosis: Self-controlled study. Dermatol Surg 2006; 32:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/60\">",
"      Richards RN. Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet. J Cutan Med Surg 2009; 13:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/61\">",
"      Smith KC, Comite SL, Storwick GS. Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg 2007; 33:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/62\">",
"      O'Riordan JM, Fitzgerald E, Gowing C, et al. Topical local anaesthetic (tetracaine) reduces pain from botulinum toxin injections for axillary hyperhidrosis. Br J Surg 2006; 93:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/63\">",
"      Smith KC, Comite SL, Balasubramanian S, et al. Vibration anesthesia: a noninvasive method of reducing discomfort prior to dermatologic procedures. Dermatol Online J 2004; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/64\">",
"      Peja M, Mad&aacute;csy L, Kassay L, Bogn&aacute;r M. Metabolic relations of serum lipids and lipoproteins in diabetic children. Acta Paediatr Hung 1983; 24:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/65\">",
"      Naumann M, Bergmann I, Hofmann U, et al. Botulinum toxin for focal hyperhidrosis: technical considerations and improvements in application. Br J Dermatol 1998; 139:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/66\">",
"      Benohanian A. What stands in the way of treating palmar hyperhidrosis as effectively as axillary hyperhidrosis with botulinum toxin type A. Dermatol Online J 2009; 15:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/67\">",
"      Blaheta HJ, Vollert B, Zuder D, Rassner G. Intravenous regional anesthesia (Bier's block) for botulinum toxin therapy of palmar hyperhidrosis is safe and effective. Dermatol Surg 2002; 28:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/68\">",
"      Keaveny TV, Fitzgerald PA, Donnelly C, Shanik GD. Surgical management of hyperhidrosis. Br J Surg 1977; 64:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/69\">",
"      Bechara FG, Gambichler T, Bader A, et al. Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage. J Am Acad Dermatol 2007; 57:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/70\">",
"      Eisenach JH, Atkinson JL, Fealey RD. Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc 2005; 80:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/71\">",
"      Drott C, G&ouml;thberg G, Claes G. Endoscopic transthoracic sympathectomy: an efficient and safe method for the treatment of hyperhidrosis. J Am Acad Dermatol 1995; 33:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/72\">",
"      Gossot D, Galetta D, Pascal A, et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thorac Surg 2003; 75:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/73\">",
"      Herbst F, Plas EG, F&uuml;gger R, Fritsch A. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limbs. A critical analysis and long-term results of 480 operations. Ann Surg 1994; 220:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/74\">",
"      Dumont P, Denoyer A, Robin P. Long-term results of thoracoscopic sympathectomy for hyperhidrosis. Ann Thorac Surg 2004; 78:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/75\">",
"      Atkinson JL, Fode-Thomas NC, Fealey RD, et al. Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin Proc 2011; 86:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/76\">",
"      Licht PB, Pilegaard HK. Severity of compensatory sweating after thoracoscopic sympathectomy. Ann Thorac Surg 2004; 78:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/77\">",
"      Chang YT, Li HP, Lee JY, et al. Treatment of palmar hyperhidrosis: T(4) level compared with T(3) and T(2). Ann Surg 2007; 246:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/78\">",
"      Licht PB, Ladegaard L, Pilegaard HK. Thoracoscopic sympathectomy for isolated facial blushing. Ann Thorac Surg 2006; 81:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/79\">",
"      Neumayer C, Zacherl J, Holak G, et al. Limited endoscopic thoracic sympathetic block for hyperhidrosis of the upper limb: reduction of compensatory sweating by clipping T4. Surg Endosc 2004; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/80\">",
"      Neumayer C, Panhofer P, Zacherl J, Bischof G. Effect of endoscopic thoracic sympathetic block on plantar hyperhidrosis. Arch Surg 2005; 140:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/81\">",
"      Sugimura H, Spratt EH, Compeau CG, et al. Thoracoscopic sympathetic clipping for hyperhidrosis: long-term results and reversibility. J Thorac Cardiovasc Surg 2009; 137:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/82\">",
"      Fibla JJ, Molins L, Mier JM, Vidal G. Effectiveness of sympathetic block by clipping in the treatment of hyperhidrosis and facial blushing. Interact Cardiovasc Thorac Surg 2009; 9:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/83\">",
"      Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg 2012; 38:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/84\">",
"      Johnson JE, O'Shaughnessy KF, Kim S. Microwave thermolysis of sweat glands. Lasers Surg Med 2012; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1257/abstract/85\">",
"      Glaser DA, Coleman WP 3rd, Fan LK, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 2012; 38:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5567 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-49496BE7AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1257=[""].join("\n");
var outline_f1_14_1257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Iontophoresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Axillary hyperhidrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Palmar hyperhidrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H536570\">",
"      Microwave energy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/32/34317\" title=\"table 1\">",
"      Medications causing sweating",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17641?source=related_link\">",
"      Approach to the patient with night sweats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=related_link\">",
"      Glycopyrrolate (glycopyrronium): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=related_link\">",
"      Oxybutynin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_14_1258="Anticoagulation in older adults";
var content_f1_14_1258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulation in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1258/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1258/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1258/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1258/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/14/1258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/14/1258/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/14/1258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the common cardiovascular disorders in older adults have a relationship to thrombosis, including ischemic heart disease, atrial fibrillation, valvular disease, and atherosclerotic vascular disease. Many of these patients require antithrombotic therapy, which raises questions regarding the appropriate use and safety of these agents, especially since older adults are at greater risk of anticoagulant-associated bleeding. The presence of concomitant physical and medical problems and the use of other drugs, especially the antiplatelet agents, increase the interactions and risks associated with anticoagulant therapy, requiring an assessment of the overall risk-benefit ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral anticoagulation is commonly indicated in the following cardiovascular conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonvalvular atrial fibrillation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardioembolic stroke (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link\">",
"       \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Valvular heart disease and prosthetic heart valves (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ischemic heart disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Left ventricular dysfunction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"       \"Indications for antithrombotic therapy in heart failure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Venous thromboembolic disease, including pulmonary embolism and deep vein thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"       \"Anticoagulation in acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral artery disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"       \"Medical management of claudication\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these conditions, such as atrial fibrillation, venous thromboembolism, and heart failure, are much more prevalent in the elderly. The risk of venous thromboembolism, for example, increases exponentially with advancing age, rising from an annual incidence of approximately",
"    <span class=\"nowrap\">",
"     30/100,000",
"    </span>",
"    at age 40 years to",
"    <span class=\"nowrap\">",
"     90/100,000",
"    </span>",
"    at age 60 years and",
"    <span class=\"nowrap\">",
"     260/100,000",
"    </span>",
"    at age 80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/2\">",
"     2",
"    </a>",
"    ]. With respect to heart failure, the Framingham Heart Study found a prevalence of 2 per 1000 in men and 1 per 1000 in women for the age range 45 to 54 years, rising to 8 per 1000 for men and 7 per 1000 women between 65 and 74 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main topic to be reviewed here will be practical issues associated with anticoagulation in the elderly. The role of anticoagulation in specific disorders is discussed in detail in the appropriate topic reviews, as noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3998197\">",
"    <span class=\"h1\">",
"     ANCILLARY INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision as to whether or not to offer anticoagulation to a specific older adult can be complex. In addition to the risks of bleeding and thrombosis, which are discussed below, there are other issues which impact on this decision. These are discussed elsewhere in UpToDate, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Presence of cognitive impairment",
"      </strong>",
"      : (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"       \"Evaluation of cognitive impairment and dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Drug prescribing in the older adult",
"      </strong>",
"      : (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=see_link\">",
"       \"Drug prescribing for older adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Outpatient monitoring of anticoagulation control",
"      </strong>",
"      : (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link\">",
"       \"Outpatient management of oral anticoagulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      <strong>",
"       dosing in the older adult",
"      </strong>",
"      : (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H23#H23\">",
"       \"Therapeutic use of warfarin\", section on 'Initial dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dosing of low molecular weight",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      <strong>",
"       in the older adult",
"      </strong>",
"      : (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H35#H35\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Special patient groups'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187674\">",
"    <span class=\"h2\">",
"     Clinician concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physician surveys have consistently cited patient age as a deterrent to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/4\">",
"     4",
"    </a>",
"    ]. This is due in part to concerns about poor compliance, difficulty monitoring patients in remote areas, recurrent falls, cognitive impairment, history of gastrointestinal bleeding, hypertension, cerebral hemorrhage, a risk of interaction with multiple other drugs, and possibly because of a decreased rate of clearance of this medication or an increased warfarin-associated inhibition of vitamin K-dependent clotting factors with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H8#H8\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'High risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although anticoagulation is of benefit for some groups of elderly patients, there are a number of important concerns about the use of anticoagulation therapy in the elderly patient, particularly an increased risk for bleeding. These factors were evaluated in a study of 323 patients &ge;80 years of age who were discharged from a hospital setting with a recommendation for treatment with oral anticoagulants and then followed for a mean of 29 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/9\">",
"     9",
"    </a>",
"    ]. The rate of major bleeding was 2.4 events per 1000 patient-months. On multivariate analysis, the following factors were associated with an increased risk of bleeding:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insufficient education concerning oral anticoagulants (odds ratio [OR] 8.8, 95% CI 2.0-50)",
"     </li>",
"     <li>",
"      More than seven regular medications (OR 6.1, 95% CI 1.2-42)",
"     </li>",
"     <li>",
"      INR values &gt;3.0 (OR 1.08, 95% CI 1.03-1.14)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To examine the relationships among age, anticoagulation intensity, and risk for intracranial hemorrhage (ICH), a case&ndash;control study was performed in 170 patients who developed ICH during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy for atrial fibrillation and 1020 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/10\">",
"     10",
"    </a>",
"    ]. Case-patients were significantly older than controls (median age 78 versus 75 years) and had higher median INRs (2.7 versus 2.3). The risk for ICH increased at &ge;85 years of age (adjusted OR 2.5, 95% CI 1.3-4.7; referent age: 70 to 74 years) and at an INR of 3.5 to 3.9 (OR 4.6; 95% CI 2.3-9.4; referent INR, 2.0-3.0). INRs &lt;2.0 were not associated with lower risk for ICH compared with INRs between 2.0 and 3.0 (OR 1.3, 95% CI 0.8-2.2). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H8#H8\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'High risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, management of anticoagulation via the use of a vitamin K antagonist should focus on maintaining the INR in the 2.0 to 3.0 range, even in elderly patients with atrial fibrillation, rather than targeting values below 2.0.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age &ge;75 is one of the risk factors for thromboembolism in patients with atrial fibrillation (AF) (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study of patients with AF and a CHADS2 score = 1 (ie, so-called intermediate risk), those with age &gt;75 as a single risk factor had threefold increased risk of stroke and mortality compared with those with hypertension alone as a single risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Danish nationwide cohort study, age &ge;75 as a single risk factor carried the greatest risk of stroke and thromboembolism compared with other single risk factors (ie, diabetes, hypertension, heart failure, etc.) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of patients with non-valvular atrial fibrillation and no CHADS(2) risk factors, the",
"      <span class=\"nowrap\">",
"       stroke/thromboembolic",
"      </span>",
"      rate per 100 person-years increased progressively with age, being 0.23, 2.05, and 3.99 for those aged &lt;65, 65 to 74, and &ge;75 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There had remained uncertainties concerning the risk-benefit ratio for the use of anticoagulation for AF in such patients, and some have recommend a lower target INR (1.8 to 2.5) than in younger patients (2.0 to 3.0). However, the risk of major bleeding at an INR &lt;2.0 is not lower than that seen at INRs in the range of 2.0 to 3.0.",
"   </p>",
"   <p>",
"    This issue was addressed in the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study, a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (INR 2.0-3.0) versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in elderly patients (age &ge;75 years) with AF when tested in a primary care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In this trial, 973 patients (mean age 81) were followed for an average of 2.7 years, with a primary thrombotic event rate (ie, fatal or nonfatal disabling stroke or significant arterial embolism) of 1.8",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    in the warfarin arm, compared with 3.8",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    in the aspirin arm (hazard ratio 0.48; 95% CI 0.28-0.80), while the risks of major hemorrhage (intracerebral as well as at all sites) were similar in the two treatment arms.",
"   </p>",
"   <p>",
"    Results of the BAFTA study, along with a meta-analysis of similar randomized trials, indicate a relative risk reduction in all strokes by adjusted-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    versus antiplatelet therapy of about 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/16\">",
"     16",
"    </a>",
"    ], and support a policy of anticoagulation for elderly subjects with AF unless there are clear contra-indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An analysis from the Atrial Fibrillation Investigators found that increasing patient age increased the risk of ischemic stroke (adjusted hazard ratio per decade increase (AHR) 1.45; 95% CI 1.26-1.66), serious bleeding (AHR 1.61; 95% CI 1.47-1.77), and cardiovascular events (AHR 1.43; 95% CI 1.33-1.53) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/17\">",
"     17",
"    </a>",
"    ]. When compared with placebo, both oral anticoagulation (OAC) and antiplatelet therapy (APT) significantly reduced the risk of ischemic stroke (OAC, AHR 0.36; 95% CI 0.29-0.45; APT, AHR 0.81; 95% CI 0.72-0.90) and cardiovascular outcomes (OAC, AHR 0.59; 95% CI 0.52-0.66; APT, AHR 0.81; 95% CI 0.75-0.88), whereas OAC significantly increased the risk of serious bleeding (AHR 1.56; 95% CI 1.03-2.37). Importantly, when compared with placebo, the relative benefit of APT for preventing ischemic stroke decreased significantly as patients aged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19385837\">",
"    <span class=\"h3\">",
"     Overall net benefit of anticoagulation in the older adult",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most, but not all, studies, thromboembolic rates and bleeding rates were both noted to increase with increasing age, calling into question whether there is a net benefit to the older patient when anticoagulation is employed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. A number of studies that have evaluated this issue are described below.",
"   </p>",
"   <p>",
"    The overall benefit to the elderly patient from anticoagulation was addressed in a review of 4202 patients from the Leiden Anticoagulation Clinic treated because of mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/18\">",
"     18",
"    </a>",
"    ]. The incidence rate (events per 100 patient-years) for",
"    <strong>",
"     thromboembolism",
"    </strong>",
"    in these adequately anticoagulated patients rose with increasing age, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;60 &mdash; 1.0 (adjusted (a)HR 1.0, reference group)",
"     </li>",
"     <li>",
"      Age 60 to 70 &mdash; 1.4 (aHR 1.3, 95% CI 0.7-2.5)",
"     </li>",
"     <li>",
"      Age 71 to 80 &mdash; 1.6 (aHR 1.7, 95% CI 1.0-3.1)",
"     </li>",
"     <li>",
"      Age &gt;80 &mdash; 2.4 (aHR 2.7, 95% CI 1.4-5.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, the incidence rate for",
"    <strong>",
"     hemorrhage",
"    </strong>",
"    increased with increasing age and was 50 to 75 percent higher than the risk for thromboembolism within each of the four age groups, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;60 &mdash; 1.5 (aHR 1.0, reference group)",
"     </li>",
"     <li>",
"      Age 60 to 70 &mdash; 2.1 (aHR 1.3, 95% CI 0.8-2.1)",
"     </li>",
"     <li>",
"      Age 71 to 80 &mdash; 2.5 (aHR 1.7, 95% CI 1.0-2.5)",
"     </li>",
"     <li>",
"      Age &gt;80 &mdash; 4.2 (aHR 2.9, 95% CI 1.7-4.8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from a large Swedish study found a significantly increased risk for major bleeding with advancing age in anticoagulated patients, although they did not find a correlation between increasing age and thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of the Atrial Fibrillation Investigators database included observations in 8932 patients from 12 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/17\">",
"     17",
"    </a>",
"    ]. Patient age increased the risk of ischemic stroke (adjusted HR per decade increase 1.45; 95% CI 1.26-1.66) as well as the risk of serious bleeding (adjusted",
"    <span class=\"nowrap\">",
"     HR/decade",
"    </span>",
"    1.61; 95% CI 1.47-1.77). When compared with placebo, the absolute benefit of antiplatelet therapy appeared to decrease with increasing age, whereas the absolute benefit of oral anticoagulation therapy increased with increasing age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187648\">",
"    <span class=\"h2\">",
"     Risk of falling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of falling and developing traumatic intracranial hemorrhage is an important concern in elderly patients taking long-term anticoagulation. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H12#H12\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'Falls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RISK OF STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the elderly with atrial fibrillation, the choice of optimal therapy to prevent stroke primarily depends upon the baseline risk of stroke. This subject is discussed in extensive detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20186640\">",
"    <span class=\"h2\">",
"     Thrombosis risk models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of models (eg, CHADS2, CHA2DS2-VASc) to determine the risk of thrombosis in patients with atrial fibrillation, and when to offer anticoagulation is discussed in depth elsewhere, and will be briefly reviewed here, since the patient's thrombosis risk has a direct impact on the net overall benefit of anticoagulation (ie, thrombotic versus bleeding risk assessment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'Risk models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of bleeding in elderly anticoagulated patients with atrial fibrillation, the rate of major hemorrhage (per 100 patient-years) was highest in those patients most in need for anticoagulation, as determined by their CHADS2 score (",
"      <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"       table 1",
"      </a>",
"      ), with rates of 2.0 to 4.3, and 20 to 23 for CHADS2 scores of zero to 2 and &ge;3, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A separate study concluded that the risk of bleeding is high (eg, number needed to harm of 10) in AF patients &ge;85 years of age with CHADS2 scores of 4 to 6, such that the use of anticoagulants should be highly individualized for this group [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a mixed retrospective and prospective cohort study of 13,559 patients with nonvalvular AF, the rate of thromboembolism in patients not receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      increased 5.3-fold as the CHADS2 score increased from 1 to 4 or more, but the rate of intracerebral hemorrhage increased only 2.3-fold within this same CHADS2 interval [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) trial, it was concluded that current thrombotic risk stratification methods in older patients with atrial fibrillation have only limited ability to predict for the risk of stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/23\">",
"       23",
"      </a>",
"      ]. It was suggested that there could be a pragmatic rationale for classifying all patients &gt;75 as being at high risk for stroke until better tools are available.",
"     </li>",
"     <li>",
"      A systematic literature search evaluated the association between CHADS2 covariates (ie, heart failure, hypertension, advanced age, diabetes, prior",
"      <span class=\"nowrap\">",
"       stroke/TIA,",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"       table 1",
"      </a>",
"      )) and the risk of bleeding in patients receiving treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . These associations were all found to be weak, with the exception of advanced age (age &ge;75 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subgroup analysis of the RE-LY trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      in atrial fibrillation, the mean age of patients was 71 years. Event rates for stroke or systemic embolism, major bleeding, intracranial bleeding, vascular death, and all-cause mortality all increased progressively with increasing CHADS",
"      <sub>",
"       2",
"      </sub>",
"      score [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above observations present a major clinical dilemma in determining the degree of overall benefit in the elderly patient, who is at increased risk for thromboembolism if anticoagulation is not given and at increased risk of bleeding if it is given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Net clinical benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK OF BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been conflicting results concerning the role of age as an independent risk factor for anticoagulant-induced hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/6,26-30\">",
"     6,26-30",
"    </a>",
"    ]. This issue was specifically addressed in a review of 4202 patients of the Leiden Anticoagulation Clinic treated because of mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/18\">",
"     18",
"    </a>",
"    ]. The incidence rate of major hemorrhage (events per 100 patient-years) was noted to rise with increasing age, as noted above.",
"   </p>",
"   <p>",
"    Similar results showing a significant correlation between age and major bleeding in anticoagulated older adults were also seen in a major Swedish study involving 18,391 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Effect of age'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other variables that influence the risk of bleeding in the elderly include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predictors of ICH during anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and related oral vitamin K antagonists have been defined, and overlap with risk factors for spontaneous ICH. These include advanced age [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/31\">",
"       31",
"      </a>",
"      ], hypertension, prior history of cerebrovascular disease, and increased intensity of anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H8#H8\">",
"       \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'High risk patients'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H20186886\">",
"       'Bleeding risk models'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"       \"Therapeutic use of warfarin\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Female sex &mdash; In a number of studies, the incidence of bleeding was noted to be higher in elderly women than in elderly men. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H29#H29\">",
"       \"Therapeutic use of warfarin\", section on 'Major risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased sensitivity to the effect of anticoagulation, perhaps due to enhanced receptor affinity or lower dietary vitamin K intake.",
"     </li>",
"     <li>",
"      Concurrent use of the many drugs that increase bleeding risk (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) or affect",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      metabolism.",
"     </li>",
"     <li>",
"      Associated comorbidity and other diseases that increase the risk of bleeding (eg, diverticulosis, malignancy, thrombocytopenia, bleeding diathesis).",
"     </li>",
"     <li>",
"      Associated comorbidity or other diseases that increase the risk of trauma and falls (eg, peripheral neuropathy, gait instability). As an example, patients at high risk for falls with atrial fibrillation are at substantially increased risk of intracranial hemorrhage, especially traumatic intracranial hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of cerebral amyloid angiopathy may be an important cause of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated lobar intracerebral hemorrhage in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/33\">",
"     33",
"    </a>",
"    ]. However, this diagnosis cannot be made prior to the event, and cerebral amyloid angiopathy may simply provide an explanation for increased intracerebral bleeding in the elderly, irrespective of warfarin use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20186886\">",
"    <span class=\"h2\">",
"     Bleeding risk models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced age (&gt;75 years), intensity of anticoagulation (especially INR &gt;4.0), history of cerebrovascular disease (recent or remote), uncontrolled hypertension, and concomitant use of drugs that interfere with hemostasis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAIDs) are probably the most important variables determining an individual's risk for major life-threatening bleeding complications while on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/6,29,30,34,35\">",
"     6,29,30,34,35",
"    </a>",
"    ]. This subject is discussed in detail separately, but will be briefly reviewed here since the patient's bleeding risk has a direct impact on the net overall benefit of anticoagulation (ie, thrombotic versus bleeding risk assessment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The systematic reviews that informed the evidence-based National Institute for Health and Clinical Excellence published guidelines on management of atrial fibrillation identified the following risk factors for bleeding with anticoagulation therapy, necessitating particular attention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;75 years",
"     </li>",
"     <li>",
"      Concomitant use of antiplatelet drugs (eg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , nonsteroidal antiinflammatory drugs)",
"     </li>",
"     <li>",
"      Multiple other drug treatments (ie, polypharmacy)",
"     </li>",
"     <li>",
"      Uncontrolled hypertension",
"     </li>",
"     <li>",
"      History of bleeding (eg, peptic ulcer, cerebral hemorrhage)",
"     </li>",
"     <li>",
"      History of poorly controlled anticoagulation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The assessment of bleeding risk should be part of the clinical assessment of patients before starting anticoagulation therapy. A number of bleeding risk models have been developed and validated to assist physicians in balancing the risks and benefits of antithrombotic therapy in outpatients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Elderly patients feature as risk factors in all of these bleeding risk scores. In the case of atrial fibrillation, many risk factors for stroke are also risk factors for bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two most commonly employed bleeding risk models for patients with AF are listed below and are discussed elsewhere in UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10666032\">",
"    <span class=\"h3\">",
"     HEMORR2HAGES risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HEMORR2HAGES risk index is based upon 11 different risk factors for bleeding, including age &gt;75 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H31#H31\">",
"     \"Therapeutic use of warfarin\", section on 'HEMORR2HAGES risk index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10666069\">",
"    <span class=\"h3\">",
"     HAS-BLED risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HAS-BLED risk score (",
"    <a class=\"graphic graphic_table graphicRef75259 \" href=\"UTD.htm?38/14/39148\">",
"     table 2",
"    </a>",
"    ) is based upon seven risk factors for bleeding, including age &gt;65 years, and has been recommended within the European Society of Cardiology and Canadian guidelines for assessing the risk of bleeding in atrial fibrillation management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H24437063#H24437063\">",
"     \"Therapeutic use of warfarin\", section on 'HAS-BLED bleeding risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187681\">",
"    <span class=\"h1\">",
"     CONCERNS ABOUT VITAMIN K ANTAGONISTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Increased sensitivity to warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients usually have increased sensitivity to the anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    as manifested by a decrease in the mean daily dose required to achieve a given anticoagulant intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/8,30,38-40\">",
"     8,30,38-40",
"    </a>",
"    ]. In one report, for example, patients &ge;75 years of age needed less than one-half the daily warfarin dose compared with patients less than 35 years of age for an equivalent level of anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism(s) involved in the increased sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in the elderly are not clear. While pharmacokinetic-based warfarin dosing estimation algorithms add to our understanding of variability in warfarin dosing requirements, in one study they overestimated doses for older patients requiring the lowest doses of warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H14#H14\">",
"     \"Therapeutic use of warfarin\", section on 'Pharmacokinetic and pharmacogenetic dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the mechanism(s) involved, initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy requires careful justification in the elderly, and overanticoagulation must be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/10,28,42\">",
"     10,28,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drug therapy is common in elderly subjects due largely to age-related coexisting disease. It is therefore important to educate elderly persons about the importance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    drug interactions any time their medication list is altered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H16#H16\">",
"     \"Therapeutic use of warfarin\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9349511\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A particularly relevant scenario exists in the elderly patient taking antibiotics. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of patients with coagulopathy induced by the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , the median age was 72, the mean number of medications taken was 6.5, and the median INR was 10.0 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/43\">",
"       43",
"      </a>",
"      ]. This interaction may be especially important in hospitalized patients, who have a high incidence of vitamin K depletion, which potentiates the effect of an antibiotic-induced reduction in vitamin K-producing gut flora [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a nested case-control study from the Medicare part D prescription drug program, exposure to any antibiotic agent within 15 days of the",
"      <span class=\"nowrap\">",
"       event/index",
"      </span>",
"      date was associated with a significantly increased risk of bleeding (OR 2.01; 95% CI 1.62-2.50) in chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      users [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/45\">",
"       45",
"      </a>",
"      ]. All six specific antibiotic drug classes examined (ie, azole antifungals, macrolides, quinolones, cotrimoxazole, penicillins, cephalosporins) were associated with a significantly increased bleeding risk. Patients whose antibiotics began &gt;60 days before the",
"      <span class=\"nowrap\">",
"       event/index",
"      </span>",
"      date did not have a significant increased risk for bleeding that required hospitalization in comparison with the control group (OR 1.25; 95% CI 0.78-2.01).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, it is reasonable to check the patient&rsquo;s INR within one week of starting an antibiotic in order to check for antibiotic-induced overanticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9349518\">",
"    <span class=\"h3\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsteroidal anti-inflammatory drug use is common in the elderly; these drugs contribute to the risk of bleeding in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/46\">",
"     46",
"    </a>",
"    ]. A particular problem arises in the setting of anticoagulated patients with atrial fibrillation who develop an acute coronary syndrome, with or without percutaneous coronary stenting, since aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is often prescribed in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/47\">",
"     47",
"    </a>",
"    ]. Such triple antithrombotic drug therapy (ie, aspirin, clopidogrel, vitamin K antagonist) requires a fine balance between stroke prevention, recurrent coronary event(s), and bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapeutic use of warfarin\", section on 'Use of NSAIDs and antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187280\">",
"    <span class=\"h2\">",
"     Initiation and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the increased sensitivity of elderly patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/50\">",
"     50",
"    </a>",
"    ], an initial dose in the range of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is preferable in the older patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/51-57\">",
"     51-57",
"    </a>",
"    ]. In patients at high risk of bleeding, and in those who are undernourished, debilitated, or have heart failure or liver disease, the starting dose should be even lower (",
"    <a class=\"graphic graphic_table graphicRef71791 \" href=\"UTD.htm?18/28/18892\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/51\">",
"     51",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of a large cohort of patients &gt;70 years of age, it was estimated that an initiation dose of 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      would be excessive for 82 percent of women and 65 percent of men [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H23#H23\">",
"       \"Therapeutic use of warfarin\", section on 'Initial dose'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H24#H24\">",
"       \"Therapeutic use of warfarin\", section on 'Maintenance therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study involving 187 elderly patients (mean age 85.6 years) utilizing a &ldquo;geriatric dosing algorithm&rdquo; in which the starting dose was 4",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for the first three days, the mean daily maintenance dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was 3.2 &plusmn; 1.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (range: 1.0 to 7.0) for the derivation sample and 3.4 &plusmn; 1.5 (range: 1.0 to 7.0)",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for the validation sample [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from Sweden described the quality of anticoagulation in 18,391 patients from 67 different centers, in which the mean time in therapeutic range for all participants was 76 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/19\">",
"       19",
"      </a>",
"      ]. The mean daily dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for these patients decreased significantly with increasing age, and was 5.6, 4.9, 4, 3.4, and 3",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for those in the age ranges of 51 to 60, 61 to 70, 71 to 80, 81 to 90, and &gt;90 years, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In less urgent cases, such as the initiation of anticoagulation for thromboprophylaxis in chronic atrial fibrillation, the estimated maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be used as the starting dose, adjusted as appropriate after five to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/54\">",
"     54",
"    </a>",
"    ]. Initial dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    in AF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3552646\">",
"    <span class=\"h3\">",
"     Correcting excessive anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study evaluated the American College of Chest Physicians recommendations for the management of overanticoagulation (",
"    <a class=\"graphic graphic_table graphicRef61288 \" href=\"UTD.htm?15/63/16380\">",
"     table 4",
"    </a>",
"    ), to determine their utility in elderly inpatients. After testing these guidelines in inpatients aged &ge;75 years with an INR &ge;5.0, it was concluded that they applied equally well to this group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187760\">",
"    <span class=\"h2\">",
"     Dabigatran versus warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative anticoagulant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is the orally active direct thrombin inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , which is approved for use in atrial fibrillation. When compared with warfarin, dabigatran was associated with significantly lower rates of both embolic events and major bleeding events, although there was a trend towards a higher risk of major bleeding with dabigatran in those aged &ge;75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/60\">",
"     60",
"    </a>",
"    ]. This has led to the recommendation in Europe to use the lower dose of dabigatran in older subjects.",
"   </p>",
"   <p>",
"    The use of this agent is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    does not require laboratory monitoring, may be less susceptible to dietary and drug interactions, and does not have",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    's narrow therapeutic window, its use may be attractive for the elderly patient who has limited ability to attend anticoagulation clinics, is taking multiple medications, and is at increased risk for bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis. However, dabigatran requires twice daily dosing, has a higher pharmaceutical cost, lacks an antidote or reversing agent for the patient who bleeds while taking the drug, needs dose adjustment for decreased renal function, and lacks long-term safety data in older adults. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Underutilization of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombotic therapy continues to be underutilized in the older adult despite the compelling evidence of the benefits of stroke reduction in patients with atrial fibrillation in this age group (AF) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/17,61\">",
"     17,61",
"    </a>",
"    ]; it has been estimated that as few as 30 to 50 percent of elderly patients without a contraindication to anticoagulation are receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a survey of anticoagulant usage in patients with AF, only 44 percent of patients with AF aged 65 to 74 years and 11 percent of patients over 75 years were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients who were not anticoagulated in one series, a contraindication to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was present in only 17 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/65\">",
"       65",
"      </a>",
"      ]. In addition, among those who were being treated with warfarin, the level of anticoagulation was often suboptimal [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a chart review of Medicare patients in Connecticut, anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was prescribed in only 53 percent of patients with AF and a prior stroke, a group at high risk for a recurrent event [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/67\">",
"       67",
"      </a>",
"      ]. Even among those ideal candidates for anticoagulation who had AF, an increased risk of stroke, and a low risk of bleeding, only 62 percent were discharged from the hospital on a warfarin regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187974\">",
"    <span class=\"h1\">",
"     VALUES AND PREFERENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an elderly patient has an indication for anticoagulation, there is a compelling need for the clinician to offer the patient detailed information concerning the risks and benefits of such treatment. Similarly, there is an equally compelling need for the patient to understand these risks and benefits and to express to the clinician",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    values and preferences concerning which risk (eg, thrombosis or bleeding) is most worrisome.",
"   </p>",
"   <p>",
"    As an example, most clinicians are concerned about the risk of fatal intracerebral bleeding should anticoagulation be initiated in the older patient, while many older patients are more fearful of the chronic, devastating effects of a thrombotic stroke should anticoagulation not be employed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of underanticoagulation (increased risk of thrombotic stroke) as well as overanticoagulation (increased risk of intracranial hemorrhage) should be of great concern should anticoagulation be undertaken, as such measures have been shown to lessen the incidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of such feared complications [",
"      <a class=\"abstract\" href=\"UTD.htm?1/14/1258/abstract/68\">",
"       68",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link&amp;anchor=H7#H7\">",
"       \"Outpatient management of oral anticoagulation\", section on 'Importance of strict INR control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of thrombotic (CHADS2 score) (",
"      <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"       table 1",
"      </a>",
"      ) and bleeding risk models (HAS-BLED) (",
"      <a class=\"graphic graphic_table graphicRef75259 \" href=\"UTD.htm?38/14/39148\">",
"       table 2",
"      </a>",
"      ) may help the clinician to determine the net benefit of anticoagulation in the individual patient.",
"     </li>",
"     <li>",
"      The choice of long-term anticoagulant (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ) depends upon a number of factors and competing preferences, such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      : Need for periodic INR measurement, multiple drug interactions, narrow therapeutic window, known long-term side effects, availability of an effective antidote, low cost.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       Dabigatran",
"      </a>",
"      : No need for periodic laboratory testing, few drug interactions, unknown long term side effects, need for twice daily dosing, high cost, drug instability issues, lack of an antidote.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More specific guidance on this issue is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H485506384#H485506384\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Indications for and choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=see_link\">",
"       \"Patient information: Taking care of bruises (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many diseases associated with stroke and thromboembolism are more common with increasing age and appropriate anticoagulation therapy reduces morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187854\">",
"    <span class=\"h2\">",
"     Considerations about treatment choices",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering anticoagulation in the elderly patient, it is useful to ask the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there a definite indication for anticoagulation (ie, a high risk of thrombosis if anticoagulation is not employed)? (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk of stroke'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is there a high risk of bleeding or strong contraindication against anticoagulation? (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk of bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Will concurrent medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , medications altering the metabolism of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ) or disease states (eg, renal disease) significantly increase bleeding risk or interfere with anticoagulation control? (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Drug-drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Are patient education, drug compliance, and attendance at an anticoagulant clinic for monitoring likely to be problems? (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link\">",
"       \"Outpatient management of oral anticoagulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Will there be regular discussions with the patient with regard to",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      understanding of the risks and benefits of continuing anticoagulation once it has been started?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20187861\">",
"    <span class=\"h2\">",
"     Reducing the risk of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful and continuing evaluation is necessary to ensure that the risks of bleeding do not outweigh the benefits from anticoagulation. If anticoagulation has been decided upon, we suggest the following for reducing the bleeding risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meticulous attention to the degree of anticoagulation when using a vitamin K antagonist, especially during the early phase (ie, first 90 days as well as the first year) of therapy, as well as in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -naive patients. (See",
"      <a class=\"local\" href=\"#H20187280\">",
"       'Initiation and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A repeat INR should be obtained at one week in patients started on antibiotics, in order to monitor for antibiotic-induced overanticoagulation. (See",
"      <a class=\"local\" href=\"#H9349511\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with atrial fibrillation, use of the direct thrombin inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      , which does not require anticoagulation monitoring, is an alternative to the use of a vitamin K inhibitor, and may be the preferred agent in some cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aggressive management of excessive anticoagulation, if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Control of hypertension, if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H10#H10\">",
"       \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'Blood pressure control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interventions to reduce the risk of falls. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"       \"Falls in older persons: Risk factors and patient evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is chosen as the anticoagulant, we suggest an initial dose in the range of 3.0 to 4.0",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for the older patient and an initial dose of 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if the patient is also frail, malnourished, or has liver disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/1\">",
"      Gage BF, Fihn SD, White RH. Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med 2001; 134:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/2\">",
"      Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/3\">",
"      Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/4\">",
"      McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/5\">",
"      Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/6\">",
"      Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003; 163:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/7\">",
"      Mungall D, White R. Aging and warfarin therapy. Ann Intern Med 1992; 117:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/8\">",
"      Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/9\">",
"      Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/10\">",
"      Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/11\">",
"      Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010; 103:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/12\">",
"      Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342:d124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/13\">",
"      Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012; 141:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/14\">",
"      Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord 2003; 3:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/15\">",
"      Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/16\">",
"      Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/17\">",
"      van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/18\">",
"      Torn M, Bollen WL, van der Meer FJ, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/19\">",
"      Wieloch M, Sj&auml;lander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/20\">",
"      Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/21\">",
"      Poli D, Antonucci E, Marcucci R, et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 2007; 121:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/22\">",
"      Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/23\">",
"      Hobbs FD, Roalfe AK, Lip GY, et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ 2011; 342:d3653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/24\">",
"      Chen WT, White CM, Phung OJ, et al. Association between CHADS���risk factors and anticoagulation-related bleeding: a systematic literature review. Mayo Clin Proc 2011; 86:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/25\">",
"      Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/26\">",
"      Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/27\">",
"      Coon WW, Willis PW 3rd. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med 1974; 133:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/28\">",
"      Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the Sixty Plus Reinfarction Study Research Group. Lancet 1982; 1:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/29\">",
"      Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989; 95:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/30\">",
"      Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003; 120:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/31\">",
"      Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/32\">",
"      Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/33\">",
"      Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000; 55:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/34\">",
"      Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/35\">",
"      Knijff-Dutmer EA, Van der Palen J, Schut G, Van de Laar MA. The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM 2003; 96:513.",
"     </a>",
"    </li>",
"    <li>",
"     National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/37\">",
"      Kakar P, Lane D, Lip GY. Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest 2006; 130:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/38\">",
"      Eccles JT. Control of warfarin therapy in the elderly. Age Ageing 1975; 4:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/39\">",
"      Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol 1979; 15:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/40\">",
"      Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol 1979; 8:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/41\">",
"      Schwartz JB, Kane L, Moore K, Wu AH. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc 2011; 12:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/42\">",
"      Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000; 160:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/43\">",
"      Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000; 63:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/44\">",
"      Jatoi A, Lennon C, O'Brien M, et al. Protein-calorie malnutrition does not predict subtle vitamin K depletion in hospitalized patients. Eur J Clin Nutr 1998; 52:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/45\">",
"      Baillargeon J, Holmes HM, Lin YL, et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med 2012; 125:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/46\">",
"      DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/47\">",
"      Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/48\">",
"      Zhao HJ, Zheng ZT, Wang ZH, et al. \"Triple therapy\" rather than \"triple threat\": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/49\">",
"      Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J 2012; 163:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/50\">",
"      Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/51\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/52\">",
"      Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/53\">",
"      Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/54\">",
"      Siguret V, Gouin I, Debray M, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med 2005; 118:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/55\">",
"      Singla DL, Morrill GB. Warfarin maintenance dosages in the very elderly. Am J Health Syst Pharm 2005; 62:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/56\">",
"      Jacobs LG, Billett HH. Office management of deep venous thrombosis in the elderly. Am J Med 2009; 122:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/57\">",
"      Moreau C, Pautas E, Gouin-Thibault I, et al. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost 2011; 9:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/58\">",
"      Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005; 127:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/59\">",
"      Pautas E, Peyron I, Bouhadiba S, et al. Reversal of overanticoagulation in very elderly hospitalized patients with an INR above 5.0: 24-hour INR response after vitamin K administration. Am J Med 2011; 124:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/60\">",
"      Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/61\">",
"      Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/62\">",
"      Sudlow CM, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ 1995; 311:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/63\">",
"      Turazza FM, Franzosi MG. Is anticoagulation therapy underused in elderly patients with atrial fibrillation? Drugs Aging 1997; 10:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/64\">",
"      Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/65\">",
"      Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997; 47:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/66\">",
"      Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997; 157:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/67\">",
"      Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998; 158:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/14/1258/abstract/68\">",
"      Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 2012; 43:1795.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1358 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1258=[""].join("\n");
var outline_f1_14_1258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3998197\">",
"      ANCILLARY INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20187674\">",
"      Clinician concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19385837\">",
"      - Overall net benefit of anticoagulation in the older adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20187648\">",
"      Risk of falling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RISK OF STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20186640\">",
"      Thrombosis risk models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK OF BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20186886\">",
"      Bleeding risk models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10666032\">",
"      - HEMORR2HAGES risk index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10666069\">",
"      - HAS-BLED risk score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20187681\">",
"      CONCERNS ABOUT VITAMIN K ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Increased sensitivity to warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9349511\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9349518\">",
"      - Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20187280\">",
"      Initiation and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3552646\">",
"      - Correcting excessive anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20187760\">",
"      Dabigatran versus warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Underutilization of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20187974\">",
"      VALUES AND PREFERENCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20187854\">",
"      Considerations about treatment choices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20187861\">",
"      Reducing the risk of bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/14/39148\" title=\"table 2\">",
"      HAS-BLED risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/28/18892\" title=\"table 3\">",
"      Warfarin dosing protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/63/16380\" title=\"table 4\">",
"      Supratherapeutic INR management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=related_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=related_link\">",
"      Patient information: Taking care of bruises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_14_1259="Life threatening ECG features";
var content_f1_14_1259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ECG features of life-threatening causes of syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Prolonged corrected QT interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brugada pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epsilon waves (arrhythmogenic right ventricular dysplasia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preexcitation syndrome (Wolff Parkinson White)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short corrected QT interval (&le;0.30 sec)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conduction delay or atrioventricular block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs of myocardial injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular hypertrophy or strain patterns",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1259=[""].join("\n");
var outline_f1_14_1259=null;
var title_f1_14_1260="DSMIV Endicott sympt depres";
var content_f1_14_1260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV* Symptoms of major depressive syndrome and substitute symptoms recommended by Endicott",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Substitute&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &Delta;Depressed mood most of the day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &Delta;Markedly diminished interest or pleasure in all, or almost all, activities most of the day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss or gain (eg, more than 5 percent of body weight in a month) or decrease or increase in appetite",
"       </td>",
"       <td>",
"        Depressed appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insomnia or hypersomnia",
"       </td>",
"       <td>",
"        Social withdrawal or decreased talkativeness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychomotor agitation or retardation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue or loss of energy",
"       </td>",
"       <td>",
"        Brooding, self-pity, or pessimism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feelings of worthlessness or excessive or inappropriate guilt",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diminished ability to think or concentrate, or indecisiveness",
"       </td>",
"       <td>",
"        Lack of reactivity; cannot be cheered up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent thoughts of death, or suicidal ideation or planning, or a suicide attempt",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    One of the symptoms marked by a delta (&Delta;) must be present for a diagnosis of major depressive syndrome. Each symptom must also meet severity (eg, \"most of the day, nearly every day\" and duration (greater than 2 weeks) criteria. Finally, the symptoms must be judged to cause clinically significant distress or impairment; they must not be due to the direct physiological effects of a medication or general medial condition; and they must not be better accounted for by bereavement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     * DSM-IV, Amer Psych Assoc, 1994. Diagnostic and statistical manual, 4th ed (DSM-IV).",
"     <br>",
"      &bull; Endicott, J. Cancer 1984; 53:2243.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1260=[""].join("\n");
var outline_f1_14_1260=null;
var title_f1_14_1261="Caries periodontitis treatment";
var content_f1_14_1261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial regimens for the prevention of dental caries and the treatment of periodontal disease in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Clinical entity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Common causative organisms",
"      </td>",
"      <td class=\"subtitle1\">",
"       Antimicrobial regimens",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"3\">",
"       Supragingival dental plaque and dental caries prevention",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       <em>",
"        Streptococcus mutans",
"       </em>",
"       , other streptococci,",
"       <em>",
"        Actinomyces",
"       </em>",
"       spp",
"      </td>",
"      <td>",
"       Fluoride-containing toothpaste (sodium fluoride, 1.1 percent or stannous fluoride, 0.4 percent) 2 or 3 times daily",
"       <strong>",
"        AND/OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluoride-containing varnishes (sodium fluoride, 5 percent) applied 3 or 4 times yearly",
"       <strong>",
"        AND/OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlorhexidine, 0.12 percent oral rinse",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Gingivitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"4\">",
"       Acute simple gingivitis",
"      </td>",
"      <td rowspan=\"4\">",
"       Streptococci,",
"       <em>",
"        Actinomyces",
"       </em>",
"       spp, spirochetes",
"      </td>",
"      <td>",
"       Penicillin G 2-4 MU IV every 4-6 hours (OR penicillin V 500 mg every 6-8 hours),",
"       <strong>",
"        PLUS",
"       </strong>",
"       metronidazole 500 mg PO every 8 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxicillin-clavulanate 875 mg PO every 12 hours or 500 mg PO every 8 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ampicillin-sulbactam 1.5-3 g IV every 6 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clindamycin 450 mg PO or 600 mg IV every 6-8 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"4\">",
"       Ulcerative or acute necrotizing ulcerative gingivitis",
"      </td>",
"      <td rowspan=\"4\">",
"       <em>",
"        Prevotella intermedia",
"       </em>",
"       ,",
"       <em>",
"        Fusobacterium",
"       </em>",
"       spp,",
"       <em>",
"        Tannerella forsythia",
"       </em>",
"       ,",
"       <em>",
"        Treponema denticoli",
"       </em>",
"       , other oral spirochetes",
"      </td>",
"      <td>",
"       Metronidazole 500 mg PO or IV every 8 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxicillin-clavulanate 875 mg PO every 12 hours or 500 mg PO every 8 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ampicillin-sulbactam 1.5-3 g IV every 6 hours",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clindamycin 450 mg PO or 600 mg IV every 6-8 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Periodontitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Early onset, \"aggressive\" or \"localized juvenile\" periodontitis",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Treponema denticola, Prevotella intermedia",
"      </td>",
"      <td>",
"       Doxycycline 200 mg PO or IV every 12 hours (only in patients 8 years of age or older)",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metronidazole 500 mg PO or IV every 8 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Adult periodontitis",
"      </td>",
"      <td rowspan=\"2\">",
"       Treponema denticoli, other oral spirochetes, Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia",
"      </td>",
"      <td>",
"       Topical minocycline microspheres (Aristin&reg;)",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Topical doxycycline hyclate periodontal extended-release liquid (Atridox&reg;)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1261=[""].join("\n");
var outline_f1_14_1261=null;
var title_f1_14_1262="Predictors stent restenosis";
var content_f1_14_1262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Incidence of restenosis increases with the number of risk factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 292px; background-image: url(data:image/gif;base64,R0lGODlh8AEkAdUAAP////8AAAAz/4CAgH8AAAAZfwAAAA0N/0BAQMDAwIaG//+AgKCgoBAQECAgIDAwMNDQ0FBQUHBwcAYGf/Dw8ODg4LCwsGBgYJCQkD8AAP/AwAAMP8PD/79AQL8AAEZGv0pK//9AQAMcvwMDPwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADwASQBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLnxoLz9ALGswJA9bXCVDV19zd3t/g4eLj5OXm5+jl2cxhzs8hIc/Ty9vXCANQA/fp/P3+/wADcrvHrsyzgkes5cOHEIDChmEOQhzy0EnFghcncpGoMeMSj8tAasTCcaJIJCLr8VsH6+TIKiUhujQickAGAjhz6typMwPD/5Y/X2qJ2XBmkZoEAihdyrQpUwJBXRkVCoUowqkUo1JM6rRrU6iysFJtYhWjViVIvapVCjaW2LFLyrJ7m3at17ZA4WaRy4zuWYdc7TrF++qtXiR8Q/5F+XdAYMFPFwOwYM0CIwgIGFQxfNhIYmV+UT6GzPYvhQcGEKDGlzqfAZZUWm+pMAB2FM6diXxOFjrhaNKEiQwwIEEIBAsMDDgYUAFAgggIJFBwyAADggsUKiAwcEHzEAbMMVSgoC+C5cnQLyRIvrw5AwQIMAgZUP36dAoSrkMwfgFBBAa0ZYMffJIdVWBuSuyGTG80/QZZcN8ZkNoA+0lgQAMIHGdABBZGAP+AhA84wB0EIj5Q3BDbNfDaAw0MgBoEyUUwgIwWYgiBhRJEYIB8IIp4AQAsuthABRUY8MAAF0SQgAH4ONCiBA48gRuCACh4DINHOSgYhBSpKKFmsulojYgfIgAABa0NZ9t200Ew4QVMYmAkfULI1sByw5nZGpoZEjfZjm46IAEGFCyJTwMNXMCclAdSeYSVxmApnJZ2cXmmcRbqaSYA23FTZp1mqlnEdkIsuU9tDm3np2zKXQPmpqkZ6hyTkyGg4gOyQhCBiENa1KijRUBajKRbkfZVY5klACdrDiRQgZxKWvAjq6EyCRupQiDKQAIYVCfBeht+2GwFYq7HGqxm3vn/nAEQKGtBAojKmux2+zUxJYLCEkPsfJSuZWkCqi43n4T7DSBiuNQCUIGIHqJowBC6SuiABRYcHMF0w7FLwQUqtvjppxCg5oBmFaBmZLu06qicd/b+CuwQ+Q6zL2DGRhaWyy9XucBLMztW81KWqnJvbjEL03O/agWdytCdFR3M0T+XdnPOTzgNDNRRK40K04dZ/QvWP2t9Ctd6ee1LzzfxpPZOPk1NNVk7B0MBeAzNTd90CeGc0j+2tUI2XGanAoGKCEQJZGpGMraQTDi/HDgqItb7p4c6nmfg4kU1DuzjpgTKsEO0DoePSvrorfnXp1PJeSlL4ooaeKHTSjpBjDL+/zbcwLhZ7QByFmehfDSZbvvtccX9i4gWoOascgmI2FzwmF+VOr7G+xLyhd4xIOLIiteeOfHF8yz8EaSj0zcrf4+1ei49jzDB+/DHL3/8I0zfSfpUrQ8ABwr0778CHJDK+GgygQMY8IAITCACJ2A/TuBPKPrjnwJAAAL/BdBvAzxKARXIwQQy0G3gQ0z1utA/ELYMJRvsoAo/6JYGdm2EXChhC6OnQRXakIV5CaEIwyDDHPoKhTZcoQs18cCX6G8IPSxMBoWTwiB6cDEJiGIC8NYFXWVGCIWSYhSz46whZDGKbCjiSI4ohCQKkIZMdCIHcWgECbnRckd5zRSchKpZuf9RQtWgVanu2Ks0iFEjZASAGTGIRoo0UY0GZGMRJASA5JipAv2JTna20x2F9ecCkuOPJBvZKi9GEY9TFN0QTAWAZanhjxMJ5CDRt0RDIvKJSWCknH4EMCSNqEQSqEADjoQoIuiSlw8AQI02RQRGDuwnpNQRy86ASoioUgEmZEJNDolIRRbTjQ/AGwP6kyY5zlIfchSCnCxjof3IZpEPO+Yo7/ijUw4RcDDcwipX0TNqqtGaQ5CQhRwwHRyRUlTDUZQ1nge6bIjqnNekiB5n9YDtNMyP71RfPLUwT6G1cj72dCI+6/Qwh3LKAMjpZm3c9IB3SUByblKSk0B1BGOCbh//n0QABVQEPDQ0syHPjOZHGpPRIG70Qw/TpQEYMDjEPfJzyQMRQRtZonohNJ/pBJ0ba9MaC1wok2W4KUJyOkPvEfCVC4zoJbRaEK768IQJ6ekNxWoJsu6ifOPoQAfScT4kVHRpF3WIWoWoU73YZG1r84AHAKu2tjnhrlvL6wD22sGf4tVRPouascSGRGh29YdpBesBHZtYyCJNsjY7rGXPKk2eajaRbK2EW3URWdBuyWWIHZti3Te/2sqvfn2FS2td6y/YjlaJhSwV33I7lt3y9i6+JW7ehocg4x53MMm9LFql59nn9vYJsTXFzHiTWqN9lreULeNvUTG7vHK3utZF/y52x3uK8gYXNN192nddG15BspeV+TiVQPbL3/76lxy0a+58QVvf7JbiLXD9r4IXzOCVoDe90F2vcnUokwFLtsD3pWd8KcxaC2ctuqTl8EicC+EAYHjCIp6Lh8MGYuCmWCgkhvCJpftik6y4ZjNmxLaEQDEvrLbGUrnxZFusCNrlx8cbBvIsYpzeHCdiSXcMVxd+rGR6Chk4RD4EZu4EnwhgNQtUrvLSrvygLCNix2EIs5jHRubXSrgRFMCAq5C85qK0uVJmPoSqJETMLai5zqRgsnWdrAgjSfHLWPgzoEUh6OcSOhFHEoOiF30Ed0RDGpBo9HEfjQgozXnKSaZ0FP/cAQ9ozMMRmgZvng2x56eCOdSilkIg55Bq+q66EO06NJ1jPYdZy6HWBL41IQakKzhqYdK8DtZEGQHsCwt7ECpT1kP9DOtkO8HXcWj2h9/MiB0hoBp9Pna1rc0EbMNB22HT7zg+8AG68gGk3/bPrsntBnO/Ad043kAB9s3vfvtbBCLwt8D9vYFxW4FjdxrqvOnNBnu7Ad+TLYAAJk7xilv84hi3eAEMXgUK6KgBJwI1w+u97EVAHDgSz7jKV65xjlOhAgKaIhPa9Ty7MYCKlxt5w0uuiJM/KOUsD3rGN86HB3iIAg5oZxKKyhDUbCeYy9X5GhzeBp9vCehCzzrFib7/h3DqYwkmw4dVKQfSqEs9DVQP4539hXWtZ53remgA8CIwbZqAPHb4EKV7z452nifC6pVqu9uDDvc8wOkBr1s6SEXJeNl1I8B8N0Pa1wB4tg/e7YXHw8YuFPKERJl3fvqd2SNvEL8jovJJE/zlVZ75O0AA0UaAubK4QyTmOW/0pB/D5E+59tSv/u0unwJ8XMMQ7a2se7knw+792Pu7qP73F2+9HZIn6eCLOcHgkKu7A4F650Of8NaPQqvD/erkU+GvhNWJYNPPtvBboftdIcDzv7919z8hP/CJzsLNL6XmR5j7/jcY80d/AiB9dlAoCLh//GcvARhagAB/AkiArGd//06QHCvSeeK2gLfRgEBDgVMAgV8xgPRngHTgACECbgqogWjBgVIDgCUWgRKIcSQ4B6/xbUcmcipoESxoYh4oBSD4FCL4fTMoB0nHSxhYfjnIgC/ogH/wg0AThNA3hHFgVRLSR1yAbC/mhDwoCFpoYlD4e1IYBxDAO0tFbUmohEvYgg+4g14YgzLYg0xAGeLxBViYYlpYX7TGhvLnhtEHh0pgIVUIe+/nhxR2h4Sog2n4hHzYcu8WLQ1Qd0h4hiuYiFvogpS4h4tYf0W3Dl+Hg5KYBIbIhXr4hasXhm+QH9ZAIMuUaIcYQqFoiYmIiZlYgK1oBK3GZ1dYi8TzimtIif9tOIu0yAe5pkWC+IG6eDu82ISjCIzB+Al1KGLJ6AddKIuZaIqS8IwcFo19MI2keHnWGAnYWIg7KDYS9D8AVHXLCIzfmGnH+DbaaATlSEH9c0GUl46zuI5uoCx1NYifOImxiDMGJmn2WI3tWARukhrF6IMFmTPvmAQBmWYDuYj4+AbVsIpXEI461JB2lWE2FZF8OJFqQBm0kZDG2I+gOI4AyZHM5JFuCJJoAIjPoXRmaJK+cYkpeW4sGYMueQaJgiudaAV7R5NZYpNQ8JBgwI3MuJNmUIPKQn5SEJRCWSz/WJQqaQZIqY4LqRoOoCM1NZNRKZVpiIdGSYc5KYFKWQb/RWUkOJeBXwmWSyiWVZlVZUmAZ2kGCUCS57eQL6ORRzCWPjaXI5iVDJEjKdgLlhYNp4ZqKEmVOOmL1CiR7UgbDrAPDVWYvGBppYZpmbaY3IaOjtmNg1eXYQBld5RaGDkJy9eRRNmZaveZSdmOhfIA6nGXdKiXi5CaK7maotWYlwiamGeb1YcMuGmVnLmb9waYQriQDOAlrsaKwml6h8CXRuCXU4acUbiQDiAitiKTbGkMwymXl6hu69Zu5vOXromV72ZVwsSdkVgM30kGd6hvAzefADef81lw5tmbr/luCXAk0GGZv/CeY3CHvvmb+RmLBQp8Raco+gSgrIB92TdX/+UJi2+ZoApaned5j8CJAV3plUuWNuyHE+sXojhhWL2IoMzYjFdonWAInApzhM5ZC9Poovyin/uJoTaqoXpAAdshUxaAIQ5qZY5JozSDoje6ohlKkHpggRfSoJ64ZHpIpASaoqI5KUkKmXrgIgAgJw1gbN0JpUMqijmqozhqpGSKBy7CLUNFm08aFlEqpmZ6pn7GoqXYjhlzR055kURKBzMKp2FpoUJXpW5ZoUd6B++Rf/ABo3pqC31KoS/4mFhapn9aqA60p3kYpo5aYpD6kaZJp95oqbnIqG+6BOX4P/TIe2OqpJJKqOjpjKCabaOqBBIkj/PomXGqqkiaqpwKCv+neaJTaZzHqau7uqqPCqgsJ6iE0KvKiKlNQJ3EKmPGeqydeqXDqgjPwjt4Y3NrmRWiyqxM4Ky5OqmUCmaeGpqvaovYJAROlzi45xax+q1xCZ63GqnhKq5yiggWQAFI9xpjBwCV065XcJimtpneugTgOqfC2pLTmrBmea5I4DyNNzqPx1akFg/yQLC6Ca+wyrANe6D2iquL0Dugk3eONxDxJaACWbBKcLDHNo7RunLIWqTzqrCNYCHtJLKiBz1fgLIQqbIOGa/w6bJUurAzq5MOSwQ6gifL0yy3p7NewLNH+a4GC7QDKrTjmmjlaqCL8HlMdXwAuxfQaQiN2qxUm7L/RWu0Hsuq97oJfwS1ZOmY4hkO7LZ9z9pkLzuBaVusV5sJbRu2hTCN8mmf/Vafgktw3TWle/t+Wat1McuFJ+u3ybq4F1q3g3a3Q0e0H0uv9/O4lHCVa0uuHEuXmKu2IFupYOC2eaupltuHb3u2HUu5lZu4Y8W5k+C5pduyoRuYqQutsttWLgOh3qB9E+qrmVut9aq3vfuBkhuoR7uoFgGi7DeiJGqiy5q719m6xWu8uGu9LcqrLiOdd2C7mouwriu6u2u3ydu531uc1Vu+yYm9pHu7WEutNOuq/Zex0ri84Ae/yNuqx9u/8su364u/26i/0sq/qju05xu7/ru59/ur/8Qbv9q7vdlbv/+bwA1suogIwe1bwa8Lu5u2uqwLwiGcvrU7wBycv/SLtgtcwiacDwYMs83LjxscllIaw3jbwuAlwoxIwjv8wuCIwjbMBKVqQbbqvterw/TFwxUXs+I7wUQkxG95IPFYQefYmtxbpwjMu0Bcwx5svvbrxY96k8GaxZ+6xejbxWiIxN0bxms8xYxZxmysxUpMYEysiT68xGqMalI8xnH8cDh8uWjMwBkMumZsrt77wEPMmvW4wh98wWlcyPN7yFrrCWIBvkTAspM8x2dcxxd2xxPnxIH8hoksxppKxoDsyGCcx5+swKzcypIswIoMx4yMqpTMuIdrtf+xrLiqrLtuLE3sq7Fy/MW+/MphA8oqSr6cjMiZAJUfEcxTy5vLXMmQTMife5GjPMKY4Mz+uMjAesTE/L6enDXILMq9LM6W3MeaGrdyS57nsI+bkc09bMw4Vs6jC8Djy7bqLGOBW7j7Rrj+vG/4Sc/1vMfAfMu4PM7kbNDMts+RfM28jNDMO8iOZs8KfcwMbXIObc0BHNHTnNAXHXGuXM0cDcWybMpcvMvxfM5JTNAoN9LKHM4t7cAo/dAdvdISvb8h/dIZLRos3cbpPMv4nM+bLNNATdIurNLnJ89NPMObsdEVDdMUbNR07NI/J9WG/NGTS9NvPNQm7dFU3clWfXX/WF3UEmzBXH3QWr3VU33WLDzWgVfW2PzTVZ3Wz5zTOo3USX3TOB3WYh3Tbv3IGtzVGKzUykvXfw3YhQ3Rfe3X1DzYau3Yj53Vks3Wbb3YfH3YeC3DpUzYKc3YS43YzAzXltfTNbnZORzUNV3SX93Ygb3Keq3Hpt0goj3ZUSzUmE3Uc43agrzTVz3bQ8nbpPzLd73WE03apQ3aoW3cea3YuY3WkF3clW3ZZu3Vbx3bdizXYP3axWzX3czd3X3Zz33dzm3Tur3d1i3Y+ozbn53ZPsjUeIzc3gfcVirc2uzdJ2nf9y3e7d3arj3e5E3Z4D3T0f3d6a3e1Q3gsF3erA3d/wJ+4OG93qsd1fQ9qBCOztgNy4b93rUN0qrt2ebt35rN3Jzt22Rd4TWq303d2ZE94AT+4Aoe4TAe4g6e4P1d4ycN4g0e4DZO4wje4xS+4RvY4dTNCNqKfC1+4RjO3z6+4Ewe5MrN4Soe35CwrlDntEke4zK+2ySe2hm+0Cgus9Pd3I7Qr/+K5dLt4kf95FB+3uh94zj+5nD+4z2Hd87xeOz8DQgAvSTa5xnQzwEd6Py2AXn+D3ve54ieE38u6Iwu0IVu6Hye6Om36I3O6ISuYIcu6X4O6JUuuJduDvCMpnY+O4/eYKYeEARy6qqO6aW+6q5uDqn+6rJu6ESKszvytf/4TdwszmhEWiRMawBlOB9O3Z68fmDDTux+YHzcg+sFvuvO/ux/d+zOG2jSTsPUzo7Grl3V/tTaDglgRArfDu6hrgnhPgrl3pbonu7qvu7s3u58cOTmjpeXcK2EIgoQIGc3t2ZWbu95Qgp7duWfgKdiZuZlBwqqkqeckK/7Ou6VQDIuBWQRKwqkZApNCwoJYCHbPgoRHwoTTwoiKwrv4SdVZusd2gkdLwo2awrbwfC34+vNA+yhcO+Gtq2ckLTWwPKS0J8DAIjBnmLKbpGc0Go4Pwlc+wklIzFe6u5Kv/RM3/RO//RQH/VSP/VUX/VJuEVn0kVSoH9aYEVA30gZYgT/mPH1G8P1Vk81EuIhsiIFzUkFdFRX1RDsa28EcCIBX79ICH/27OBGn4QP4CEEf18NFkB35HFFZVI6WFQellENMAIbA4JJnCQwo0Qh2xL36HEdfT8ZFDJKIsIch2oeQlAB+WEe7LEo1gH61DGGAAAB/fEfei8MRnInVoUP2EIqw7FLF8IiMM95XAkkLfIit79Qvi8kon8hfRb81vAaMTIjVEVVMrmcCMkhBgPsM9Ui/TFMN0Ic/9qkwD4nSfL6wZAajkQrtf8wB1Ut2bAnCPkmTDIcxuYmxWFVPBJu7j8wanokmrEkErBLawkECAMAUBkgHIYExsAgVgAGBLHxAFAM/5GoFQAxOCQYCpFcNp/RafWa3Xa/4XH5nF633/F5/d4uBQgNBv6GBgEGlKKmDhMSiaQSpAYkExbNIAUvG8sqDRGPDAwkIBtIx8qEiqoYLpQ4Hac0/fyILBAaDLj4dHd5e31/gYOFh+X8IAMBIrIkbjsZ/SpxE1gxAEgZlhhcyRocEpQhNMk4FzFEGbIgw7LMUCEjEoQSvB4SGLS+EiqULQ6rZ6dZSECKWEGDBxEmVLiw4CxWgiAkifBgSDRFiAzcCkUEgrIv/RCZgUDRgRNxRMgpsZAkC4VMQqqRQQWAVRVEFigiO2QAAgVlDSS8epLzQTiGR5EmVbqUaVOnT6FGlXQ6lWpVq1exZtW6lWtXr1/BhhU7lmxZs2fRplW7lm1bt2/hxpU7l25du3fx5tW7l29fv38BBxY8mHBhw4cRJ1a8mHFjx48hR5Y8mXJly5cxZ9a8mXNnz59BhxY9mnRp06dRp1a9mnVr169hx5Y9m3Zt21yDAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rate of stent restenosis and the need for target lesion revascularization (TLR) increases as more of the strongest risk factors are present. Risk factors include diabetes, multiples stents, and minimum luminal diameter after stenting &lt;3 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kastrati A, Schomig A, Elezi S, et al. J Am Coll Cardiol 1997; 30:1428.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1262=[""].join("\n");
var outline_f1_14_1262=null;
var title_f1_14_1263="Extrusion injury";
var content_f1_14_1263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extrusion injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extrusion of the primary central incisors. The teeth are centrally dislocated from the socket, and the periodontal ligament is lacerated and inflamed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from McTigue, DJ. Managing traumatic injuries in the young permanent dentition. Courtesy of Dennis J McTigue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_14_1263=[""].join("\n");
var outline_f1_14_1263=null;
